NOVEL FACTORS WHICH MODIFY GENE TRANSCRIPTION AND METHODS OF USE THEREFOR

Abstract: Eukaryotic RNA polymerase II holoenzymes that contain RNA polymerase II and one or more regulatory proteins are described. These holoenzymes selectively initiate transcription in vitro when supplemented with general transcription factors. The regulatory proteins act positively and negatively to regulate transcription initiation, at least in part, via functional interactions with RNA polymerase II.

Description: NOVEL FACTORS WHICH MODIFY GENE TRANSCRIPTION AND METHODS OF USE THEREFOR Background of the Invention The regulation of cellular gene expression occurs primarily at the level of transcription initiation by RNA polymerase. Regulated transcription initiation by RNA polymerase II in higher eukaryotes involves the formation of a complex with general transcription factors at promoters (Sawadogo, M. and Sentenac, A., Ann. Rev. Biochem. 59:711-754 (1990) . One of these factors, transcription factor IID (TFIID) , contains the TATA-binding protein (TBP) , which is able to bind directly to promoter DNA. The remaining components of the transcription initiation complex include RNA polymerase II and the initiation factors TFIIA, TFIIB, TFIIE, TFIIF, TFIIH, and TFIIJ. These components associate with TFIID-bound promoter DNA to form a transcription initiation complex. Sequence-specific DNA-binding proteins appear to regulate the establishment and activity of transcription initiation complexes, possibly through interactions with TFIIB and TBP and additional factors that make up TFIID. Several high molecular weight complexes containing TBP have been identified in extracts from human and Drosophila cells (Gill, G, and Tjian, R. , Curr. Qpin. Gen. Dev. 2:236-242 (1992); Sharp, P.A., Cell 68:819- 821 (1992)) . One of these complexes is TFIID, which contains at least eight TBP-associated factors (TAFs) (Pugh B.F., and Tjian, R.J. Genes Dev. 5:1935-1945 (1991) ) . A second complex is the RNA polymerase I promoter selectivity factor, SL1, which contains TBP and three TAFs (Comai, L., et al . , Cell 68:965-976 (1992)) . A third complex is a component of the RNA polymerase III factor TFIIIB, which consists of TBP and two TAFs (Taggart, A.K.P., et al . , Cell 71:1015-1028 (1992)) . Some of the TAFs associated with these complexes appear to function as transcriptional coactivators by providing a functional link between sequence-specific regulators and TBP (Dynlacht, B.D., et al . , Cell 66:563-576 (1991)) . The RNA polymerase II carboxyl-terminal domain (CTD) is another component of the transcription apparatus that can bind to TBP (Usheva, A., et al., Cell 69:871-881 (1992)) . The CTD is a highly conserved and apparently unique feature of the largest subunit of RNA polymerase II (Young, R. A., Ann. Rev. Biochem. 60:689-715 (1991)) . The CTD contains 26-52 repeats, depending on the organism, of the consensus heptapeptide sequence, Tyr-Ser-Pro-Thr-Ser-Pro-Ser. Deletion mutations that remove most or all of the CTD are lethal to cells (Nonet, M. , et al . , Cell 50:909-915 (1987) ) . CTD partial truncation mutations cause defects in growth and inducible gene expression in vivo and produce substantial defects in transcription initiation in vi tro (Liao, S.M., et al., Genes Dev. 5:2431-2440 (1991) ) . An important feature of RNA polymerase II molecules recruited into the initiation complex is their association with RNA polymerase-associated pro¬ teins (RAPs) (Conaway, J.W., et al., J. Biol . Chem. 266:17721-17724 (1991)) . Two mammalian proteins, RAP30 and RAP74, have been identified as components of the general transcription factor TFIIF (Flores, 0., et al . , J. Biol. Chem. 263:10812-10816 (1988)) . Despite this knowledge of the components of the RNA polymerase II transcription initiation complex, two major questions have not been addressed until now. First, how do RNA polymerase II and the general initiation factors interact with one another in vivo? For example, it is not clear whether RNA polymerase II and general factors assemble in a sequential manner on promoter DNA, or whether a large complex of these components assembles prior to association with DNA. Second, how do transcriptional regulators interact with the transcription initiation complex? Thus, we do not know whether interactions occur only between regulators and the subunit of TFIID, or whether there are additional interactions with other components of the initiation complex. Summary of the Invention The present invention relates to RNA polymerase II holoenzyme complex. An RNA polymerase II holoenzyme complex of the present invention is a multisubunit complex comprising RNA polymerase II and one, or more, regulatory components. The regulatory components include, eukaryotic regulatory proteins, for example, yeast and mammalian SRB (Suppressor of RNA polymerase B) proteins and yeast and mammalian SWI and SNF proteins. The RNA polymerase II holoenzyme is capable of initiating transcription and is responsive to activators. Additional components associated with the RNA polymerase holoenzyme can include one, or more general transcription factors (also referred to herein as GTFs) and other components necessary and sufficient for responding to transcriptional activators. The RNA polymerase II holoenzyme described herein plays a key role in the initiation of transcription in eukaryotic cellular organisms. DNA transcription by the RNA polymerase II holoenzyme is stimulated by activator proteins, a feature not observed with purified RNA polymerase II and general transcription factors alone. Applicants have identified and characterized eukaryotic RNA polymerase II holoenzyme complexes and their components, including those of mammalian, non- mammalian (including for example, yeasts, fungi, parasites and insects) and human origin. In one embodiment, yeast regulatory proteins, identified herein as SRB2, SRB4, SRB5, SRB6, SRB7, SRB8, SRB9, SRB10 and SRB11, which act as positive and negative regulators of the activity of RNA polymerase II are described. Encompassed by this invention are yeast SRB proteins SRB2, SRB4, SRB5, SRB6, SRB7, SRB8, SRB9, SRB10 and SRB11, the amino acids encoding these SRB proteins, and variants or derivatives (e.g., mutant SRB proteins) thereof, and antibodies reactive with the SRB proteins. The SRB proteins comprise the SRB complex which is tightly associated with the RNA polymerase II carboxy terminal domain, or CTD. Also described herein is the cloning and sequencing of the first human SRB and the purification and characterization of a mammalian RNA polymerase II holoenzyme. hSRB7 is 35% identical to ySRB7, complements a ySRB7 deletion, and, like its yeast counterpart, binds to the carboxyl terminal domain of RNA polymerase II. hSRB7 is part of a mammalian holoenzyme complex, and results described herein show that this mammalian holoenzyme complex supports activated transcription. As further described herein, the RNA polymerase II holoenzyme of the present invention includes additional regulatory components, including global gene regulators comprising SWI and SNF gene products. The SWI and SNF gene products are collectively referred to herein as SWI/SNF proteins. The SWI/SNF proteins, or polypeptides, play a key role in the regulation of gene expression. The regulatory function of gene expression of the SWI/SNF proteins includes chromatin remodeling. More specifically, the SWI/SNF proteins provide the RNA polymerase II the holoenzyme capacity to disrupt nucleosomal DNA and, thus, facilitate stable binding of various components of the transcription initiation complex at specific promoters. The SWI/SNF proteins encompassed by the present invention form a multisubunit complex with the SRB proteins, referred to herein as the SRB/SWI/SNF complex. The SRB/SWI/SNF complex associates with the RNA polymerase II CTD. Encompassed by the present invention are the SWI/SNF proteins which comprise the SRB/SWI/SNF complex. Also encompassed by this invention are the DNA sequences encoding the eukaryotic, e.g., yeast and mammalian, SRB proteins and novel SWI/SNF proteins, the complementary strands of these DNA sequences, and allelic variations thereof, and nucleic acid probes that are sufficiently complementary to a SRB or SWI/SNF DNA sequence that they selectively hybridize to that SRB or SWI/SNF DNA sequence. This invention further relates to methods of modifying gene transcription by substances that bind to, or interact with, SRB proteins or SWI/SNF proteins; the SRB genes and SWI/SNF genes encoding the proteins, or the SRB or SWI/SNF mRNAs. Such substances can either prevent, or enhance, the formation of the RNA polymerase II holoenzyme, or, if the holoenzyme complex is formed, prevent, or enhance, the function of the holoenzyme as an initiator of transcription. Substances that bind to, or interact with the SRB proteins or SWI/SNF proteins; SRB genes or SWI/SNF genes; or SRB or SWI/SNF mRNAs can also modify the influence that SRB or SWI/SNF proteins have on RNA polymerase II, or on other transcription factors essential to gene transcription. Moreover, differences in SRB and SWI/SNF protein homolog (e.g., differences in the yeast and human SRB7 gene or protein sequences) can be exploited to design therapeutic compounds or drugs, that target pathogenic eukaryotes, e.g., the fungus Candida, and inhibit gene transcription in the pathogen without affecting gene transcription in the mammalian or human host. This invention also relates to a method of in vi tro transcription employing the purified RNA polymerase II holoenzyme and to the use of this method to identify substances, both naturally-occurring, and synthetic, that modify gene transcription. This invention further relates to methods of detecting SRB genes, or SWI/SNF genes, and gene products in a cell or in biological fluids using nucleic acid probes which hybridize to DNA encoding the SRB protein or SWI/SNF protein, or to SRB or SWI/SNF mRNA, (e.g., antisense nucleotides) or antibodies which bind to the SRB or SWI/SNF gene product. Brief Description of the Drawings Figure 1A shows the restriction map of a 1.95 kb BstEII-EcoRI DNA fragment from pCT21 containing the SRB2 gene (B, BstEII; E, EcoRI; N, Ncol; P, Pstl; S, SadI) . The SRB2 transcript is indicated above the map. The entire coding region of SRB2 was replaced with a 1.75 kb BamHI DNA fragment containing the HIS3 gene to create the deletion allele srb2Δl. Figure IB shows the DNA sequence of the 1.95 kb BstEII-EcoRI DNA fragment containing the SRB2 gene (SEQ ID NO: 1) and the deduced sequence of the SRB2 protein (SEQ ID NO: 2) is shown below the sequence of the gene. The transcription initiation site is indicated by the horizontal arrow. The splice donor and splice acceptor sites are underlined. The TGCTAACA splice branch point site is boxed. The SRB2-1 mutation is a C to A transversion (nt 768) that changes as 14 from Pro to His. Figure 2A, 2B and 2C shows the DNA sequences and predicted amino acid sequences of the SRB4 (SEQ ID NO: 3 and 4) , SRB5 (SEQ ID NO: 5 and 6) and SRB6 (SEQ ID NO: 7 and 8) proteins, respectively. Figure 3A-3E shows the results of experiments demonstrating that SRB2 and SRB5 are essential for efficient transcription in vi tro. Figure 4A and 4B shows the results of experiments demonstrating that SRB2 and SRB5 are essential for efficient preinitiation complex formation. Figure 5A-5C shows the purification scheme of the SRB complex and results of the purification. Figure 6A-6E shows the results of experiments demonstrating that the RNA polymerase II holoenzyme is a complex of RNA polymerase II and initiation factors. Figure 7A and 7B shows the results of experiments demonstrating that transcription by the RNA polymerase II holoenzyme is stimulated by GAL4-VP16. Figure 8 summarizes extragenic suppressors of CTD truncation mutants. Figure 9 shows the DNA sequence and predicted amino acid sequence of SRB7 (SEQ ID NO: 9 and 10) . Figure 10A and 10B shows the DNA sequence and predicted amino acid sequence of SRB8 (SEQ ID NO: 11 and 12) . Figure 11A, 11B and 11C shows the DNA sequence and predicted amino acid sequence of SRB9 (SEQ ID NO: 13 and 14) . Figure 12 shows the DNA sequence and predicted amino acid sequence of SRBIO (SEQ ID NO: 15 and 16) . Figure 13 shows the DNA sequence and predicted amino acid sequence of SRB11 (SEQ ID NO: 17 and 18) . Figure 14 shows the influence of SRB2 and SRB8 alleles on growth phenotypes of RNA polymerase II CTD truncation mutants. Figure 15A and 15B shows that SRB2 and SRB4-SRB9 are components of an RNA polymerase II holoenzyme. Figure 16 depicts the RNA Polymerase II holoenzyme model. Figure 17A shows the DNA sequence (SEQ ID NO.: 36) and the predicted amino acid sequence of hSRB7 (SEQ ID NO. : 37) . Figure 17B compares the predicted amino acid sequence of hsSRB7 and its yeast homolog. Detailed Description of the Invention The present invention relates to the discovery of an RNA polymerase II holoenzyme complex capable of site-specific initiation of gene transcription. RNA polymerase II holoenzymes described in the present invention are multisubunit complexes that contain RNA polymerase II and one, or more, regulatory proteins. Importantly, as described herein, the RNA polymerase II holoenzyme plays a key role in the initiation of transcription in eukaryotic organisms. Specifically, eukaryotic RNA polymerase II holoenzymes described in the present invention are high molecular weight (1-4 Md) , multisubunit complexes that contain RNA polymerase II and one, or more, regulatory proteins. The regulatory proteins as described herein, include SRB proteins, SWI proteins and SNF proteins. The SRB regulatory proteins, identified herein as SRB2, SRB4, SRB5, SRB6, SRB7, SRB8, SRB9, SRBIO and SRB11, act as positive (enhancing) and negative (suppressing) regulators of the activity of RNA polymerase II. The SRB proteins can have multiple roles in the holoenzyme. The SRBs can act as a regulatory "glue" that stabilizes interactions between RNA polymerase II and transcription factors. They may also confer some degree of responsiveness to transcriptional activators, perhaps serving the holoenzyme in a manner functionally analogous to TAFs in TFIID. Furthermore, the SRBs may regulate events subsequent to initiation complex formation, for example, phosphorylation of the CTD and promoter clearance. The eukaryotic RNA polymerase II holoenzyme, comprising RNA polymerase II and at least one SRB protein, is capable of initiating efficient selective transcription when supplemented with additional proteins involved with gene transcription and is responsive to transcriptional activators. The SWI and SNF proteins described herein, collectively referred to as SWI/SNF proteins, typically form a complex which associates with the SRB proteins. The SWI/SNF proteins of the SRB/SWI/SNF complex can include, for example, SWI1, SWI2/SNF2, SWI3, SNF5, SNF6 and SNF11. The SRB/SWI/SNF protein complex can also include additional regulatory proteins or components necessary and sufficient to confer gene transcription activity to the holoenzyme. The SWI and SNF proteins described herein are involved with gene transcription activity and have been implicated in chromatin remodeling. The eukaryotic RNA polymerase II holoenzyme, comprising RNA polymerase II, at least one SRB protein and at least one SWI/SNF protein, is capable of ATP-dependent nucleosome disruption activity. The proteins involved with gene transcription can be divided into three groups, described as follows: 1) subunits of RNA polymerase needed for some or all of the stages of transcription, but are not specific for individual promoters; 2.) transcription factors that bind RNA polymerase before, during, or after it forms an initiation complex, although they are not part of the free enzyme (these factors are likely to be needed for transcription to initiate at all promoters or,for example, to terminate); and 3.) transcription factors that bind specific sequences in the target promoters. (If the same sequences were present in all promoters, these factors would be part of the general transcription apparatus. If some sequences are present only in certain classes of promoters, factors that recognize them could be needed specifically to initiate at those promoters.) Transcription factors are also referred to herein as initiation factors. The general transcription factors associated with the RNA polymerase II holoenzymes described herein include, for example, in yeast, the transcription factors b, e, and g and in mammals, including humans, the mammalian transcription factors TFIIH, TFIIB, TFIIE and TFIIF. The association of the holoenzyme with general transcription factors can vary within the cell at different points during the transcription process, or can vary from organism to organism. For example, the RNA polymerase II holoenzyme is capable of initiating gene transcription when interacting with (also referred to herein as associated with, or supplemented with) transcription factor a, in yeast, but with TFIIE and TATA-binding protein in humans. (TATA-binding protein is also referred to herein as TBP, which is a component of a TFIID multisubunit complex containing TBP- associated factors (TAFs) which binds selectively to promoter DNA) . Surprisingly, the RNA polymerase II holoenzymes are responsive to activators, such as the GAL4-VP16 activator protein, a feature not observed with purified yeast GTFs and polymerase II alone. Thus, the eukaryotic RNA polymerase II holoenzymes can be associated with additional components necessary and sufficient for responding to transcriptional activators, such as GAL11/SPT13. The holoenzymes can also be associated with proteins implicated in transcriptional repression, such as a kinase-cyclin protein pair. (Liao, S.M., et al . , Nature 374:193-196 (1995); Kuchin, S, et al . , Proc. Natl. Acad. Sci. U.S.A.. 92:4587-4590 (1995)). The present invention encompasses the SRB proteins SRB2, SRB4, SRB5, SRB6, SRB7, SRB8, SRB9, SRB10 and SRB11, the SRB amino acid sequences, and variants or derivatives thereof. Also intended to be encompassed by the present invention are proteins described herein with reference to specific SRB amino acid sequences, as well as the SRB proteins which include one, or more "silent changes" in the amino acid sequence. Such silent changes in the amino acid sequence may not reflect the exact SRB amino acid sequence described herein, but nevertheless, do not alter the essential function, or activity of the SRB protein, i.e., as a transcriptional regulator. For example, one, or more, amino acid residue(s) may differ in an amino acid sequence from a SRB amino acid sequence described herein, yet still retain the ability to function as an regulator of gene transcription. Also encompassed by this invention are the DNA and RNA sequences encoding the SRB proteins, the complementary strands to these DNA/RNA sequences, and nucleic acid sequences (e.g., nucleic acid probes) that are sufficiently complementary to a SRB DNA/RNA sequence to selectively hybridize to that SRB DNA/RNA sequence. Sufficiently complementary is defined herein to mean that the nucleic acid sequence may not reflect the exact sequence described herein, but must be sufficiently complementary to hybridize to the sequence encoding the SRB protein. For example, non- complementary bases can be interspersed in the exact SRB DNA sequence, or a sequence can be longer or shorter than the exact SRB sequence, yet the sequence has sufficient complementarity to hybridize to the exact SRB sequence. The present invention further encompasses the SRB/SWI/SNF complex which associates with the RNA polymerase II CTD and regulates gene expression. More specifically, encompassed by the present invention is a multi subunit, (e.g., multiprotein) complex comprising one, or more SAB proteins and one, or more SWI/SNF proteins and has the ability to initiate gene transcription, for example, by chromatin remodeling, or nucleosome disruption. This invention further relates to methods of modifying gene transcription by substances that bind to, or interact with, one or more SRB proteins, SWI/SNF proteins, or the DNA/RNA encoding the SRB or SWI/SNF proteins and, thus, modify the influence of the SRB or SWI/SNF proteins on RNA polymerase II, or on other transcription factors essential to gene transcription. Interact, as used herein, includes inhibiting or promoting post-translational modification of a SRB or SWI/SNF protein. For example, a method of inhibiting gene transcription in a cell by inhibiting the phosphorylation of the CTD of RNA polymerase II via the SRB protein, or inhibiting the phosphorylation/activation of the SRB protein itself, is encompassed by the present invention. Substances that bind to, or interact with, one, or more SRB or SWI/SNF proteins or the DNA/RNA encoding these regulatory proteins can prevent, or enhance, the formation of the RNA polymerase II holoenzyme complex, thus, inhibiting or enhancing gene transcription. For example, antisense, or nonsense nucleotide sequences that hybridize with the SRB or SWI/SNF DNA or RNA and completely inhibit, or decrease, their translation or transcription can prevent the formation of the holoenzyme complex and inhibit gene transcription. Alternatively, even though the holoenzyme complex is formed, substances that bind to, or interact with the SRB or SWI/SNF proteins, can prevent or enhance the function of the complex in the transcription process. These substances include antibodies that are reactive with, or bind to, the SRB proteins. It is important to note that therapeutic compounds can be identified and/or designed that modify gene transcription by interacting with SRB or SWI/SNF proteins of a eukaryotic pathogen without modifying gene transcription in the host. This invention also relates to a method of in vi tro transcription employing the purified RNA polymerase II holoenzyme and to the use of this method to identify substances, both naturally-occurring, and synthetic, that modify gene transcription. This invention also encompasses methods of identifying additional components, or proteins, that are functional equivalents of the SRB and SWI/SNF proteins described herein, and, therefore, have activity that is equivalent to the SRB and SWI/SNF proteins of the RNA polymerase II holoenzyme. This invention further relates to methods of identifying substances that modify gene transcription, and methods of treating disease conditions resulting from insufficient, or increased, production of, SRB proteins, or production of abnormal SRB or SWI/SNF proteins. These methods include the use of substances that bind to, or interact with, the SRB or SWI/SNF proteins, (naturally occurring and biologically active, also referred to herein as wildtype SRB proteins) genes encoding the SRB or SWI/SNF proteins, SRB or SWI/SNF messenger RNA, or the use of genetically altered SRB or SWI/SNF proteins. The present invention further encompasses a method of identifying a component that has activity functionally equivalent to the activity of a SRB or SWI/SNF protein by evaluating the activity of the candidate protein to compensate for a deleted SRB or SWI/SNF protein in the RNA polymerase II holoenzyme. More specifically, a method is encompassed to identify a protein that has activity functionally equivalent to the activity of a SRB or SWI/SNF protein comprising inhibiting, either partially or completely, the activity of SRB or SWI/SNF protein in the RNA polymerase II holoenzyme; providing a candidate protein to be tested for SRB or SWI/SNF protein activity; associating the candidate protein with the RNA polymerase II holoenzyme; and determining the activity of the RNA polymerase II holoenzyme associated with the candidate protein, wherein if the candidate protein is functionally equivalent to the inhibited SRB or SWI/SNF protein, the RNA polymerase II holoenzyme retains its ability to initiate gene transcription. The discovery of novel SRB proteins which modify gene transcription was made possible by a combination of genetic and biochemical selection techniques designed to identify transcription factors involved in RNA polymerase II carboxyl terminal domain (CTD) function. Most, if not all, of these proteins are tightly associated with the RNA polymerase II holoenzyme. Among the SRB proteins are both positive and negative regulators, indicating a dual role for CTD-associated factors in the initiation of transcription. The CTD is a highly conserved and apparently unique feature of the largest subunit of RNA polymerase II. Depending on the organism, the CTD contains up to about 52 repeats of the consensus heptapeptide sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser. A subset of the RNA polymerase II molecules in yeast and mammalian cells has highly phosphorylated CTDs, and RNA polymerase II molecules lacking phosphorylation on the CTD are preferentially recruited into the initiation complex. Deletion mutations that remove most, or all, of the CTD are lethal to cells. CTD partial truncation mutations, however, cause defects in growth and gene expression in vivo and produce substantial defects in transcription initiation at multiple promoters in vi tro. Thus, suppression analysis of conditional CTD truncation mutations in yeast has been used to identify factors which influence CTD function. Cloning and Sequence Analysis of SRB2 The isolation of suppressors of _?acc_ιaro.τιyces cerevisiae RNA polymerase II CTD truncation mutations led to the identification of a dominant suppressing allele, SRB2-1, and the isolation of DNA clones containing SRB2-1 and its wild type counterpart, SRB2 (Nonet, M. L. and Young, R. A., Genetics 123:715-724 (1989)) . The position of SRB2 within a genomic DNA clone is shown in Figure 1A. The sequence was determined for SRB2 and its surrounding DNA, as shown in Figure IB (SEQ ID NO: 1) . The SRB2 gene was shown to encode a TBP-binding protein. (Koleske, A.J., et al . , Cell 69:883-894 (1992)). The predicted SRB2 protein is 210 amino acids long (SEQ ID NO: 2) and has a molecular mass of 23 Kd. It is a hydrophilic protein rich in serine, threonine and tyrosine residues, and it is acidic, with a predicted pK, of 5.2. (See Example 1) . The SRB2 gene was identified through analysis of extragenic suppressors of CTD truncation mutations, as described in Example 1. The dominant, gain-of-function mutation SRB2-1 specifically suppresses CTD truncation mutations. Cells lacking SRB2 and cells lacking a large portion of the CTD exhibit the same set of conditional growth phenotypes and have the same defects in gene expression. (See Figure 2) . While the presence of SRB2-1 causes cells with severe CTD truncations to behave as if the CTD was longer, the loss of SRB2 has the opposite effect. The allele specificity of the SRB2 suppressor, the identical behavior of cells with CTD truncations and cells lacking SRB2 all indicate that SRB2 and CTD are involved in the same process during initiation. To identify additional components of the transcription apparatus that affect CTD function, extragenic suppressors of a Saccharo yces cerevisiae RNA polymerase II CTD truncation mutant were isolated, as described in Example 2. The cold-sensitive phenotype of cells containing RNA polymerase II CTDs with only 11 intact heptapeptide repeats (rpblΔl04) was exploited to obtain 85 independent suppressing isolates, of which approximately one-third were dominant and two-thirds recessive. The dominant suppressing isolates were chosen for further study. Genetic analysis revealed that all of the dominant mutations occurred in four SRB genes: SRB2, SRB4, SRB5, and SRB6. Additional analysis revealed that SRB4, SRB5, and SRB6 were newly identified genes. Two genetic assays were performed to obtain support for a functional relationship between the new SRB gene products and the CTD. The ability of the suppressing alleles of SRB4, SRB5, and SRB6 to suppress all of the phenotypes associated with the CTD truncation mutation rpblΔl04 was investigated. These phenotypes include cold- and temperature-sensitive growth, inositol auxotrophy, and the inability to utilize pyruvate as a carbon source. Cells containing either SRB4-1, SRB5-1, or SRB6-1 suppress all of these defective phenotypes, as does SRB2-1. To assess whether the suppressing activities of SRB4-1, SRB5-1, and SRB6-1 are specific to CTD mutations, the ability of the SRB alleles to suppress the conditional phenotypes associated with mutations elsewhere in RNA polymerase II was investigated. SRB4-1, SRB5-1, and SRB6-1 generally do not suppress the conditional and auxotrophic phenotypes associated with rpbl point mutations. SRB4-1, SRB5-1, and SRB6-1 do suppress the cold-sensitive phenotype of the rpbl-14 mutation. This is the same type of suppression specificity shown by SRB2-1, and this argues that SRB2, SRB4, SRB5, SRB6, and the CTD are involved in the same process in transcription initiation. Cloning and Sequence Analysis of SRB4. SRB5. and SRB6 Genomic DNA clones containing SRB4-1, SRB5-1, and SRB6-1 were isolated by taking advantage of their ability to suppress dominantly the cold-sensitive phenotype of a cell containing the CTD truncation mutation rpblΔl04. Genomic DNA was isolated from strains containing the dominant suppressing alleles of SRB4, SRB5, and SRB6. Libraries were constructed in a yeast centromeric plasmid containing the URA3 gene as a selectable marker. These libraries were transformed into yeast cells containing cold-sensitive CTD truncation mutation, and genomic clones were isolated from Ura + transformants able to grow at 12 ° C. The mutant genes were further localized by constructing subgenomic libraries with fragments of the SRB4-1, SRB5-1, and SRB6-1 genomic inserts and again selecting for Ura + transformants able to grow at 12 ° C. Genomic clones with the smallest inserts were identified and sequenced. The wild-type allele of SRB4 was cloned from a wild-type genomic DNA library. Wild-type SRB5 and SRB6 alleles were obtained by plasmid gap repair in vivo Plasmids containing the wild-type SRB4, SRB5, and SRB6 genes did not suppress the cold-sensitive phenotype of CTD truncation mutants, confirming that in each case the correct locus was cloned. SRB4, SRB5, and SRB6 were physically mapped using the prime clone grid filters of the yeast genome (provided by L. Riles and M. Olson, Washington University) . SRB4 maps to the right arm of chromosome V, approximately 40 kb from the centromere (λ clones 5961 and 6224) . SRB5 maps to the right arm of chromosome VII, approximately 30 kb centromere proximal to SPT6 (λ clones 5146 and 4624) . SRB6 maps to the right arm of chromosome II, approximately 75 kb centromere distal to CDC28 (λ clone 4796) . DNA fragments containing SRB4 (SEQ ID NO: 3), SRB5 (SEQ ID NO: 5), and SRB6 (SEQ ID NO: 7) were sequenced, and the open reading frames were established by unidirectional deletion analysis and identification of the suppressing mutations. The predicted SRB4 protein is 687 amino acids long (SEQ ID NO: 4) and has a molecular mass of 78 kd (Figure 2A) . SRB5 is predicted to be 307 amino acids in length (SEQ ID NO: 6) with a molecular mass of 34 kd (Figure 2B) . The predicted SRB6 protein is 121 amino acids long (SEQ ID NO: 8) and has a molecular mass of 14 kd (Figure 2C) . A search of sequence data banks revealed that SRB4, SRB5, and SRB6 did not have significant sequence similarity to pre¬ viously identified proteins. One notable feature of the SRB proteins is their acidic content. The predicted pK values of SRB2, SRB4, SRB5, and SRB6 are 5.2, 5.1, 4.7, and 4.6, respectively. The suppressing mutations in all three genes were identified by comparing the complete sequences of the cloned wild-type and suppressing alleles of SRB4, SRB5, and SRB6. In each case, the alterations were singlepoint, missense mutations. The mutation in SRB4-1 changes glycine 353 to cysteine. The SRB5-1 mutation changes threonine 22 to isoleucine, and the SRB6-1 mutation changes asparagine 86 to lysine. To determine whether the SRB genes are essential for cell viability, the entire coding region of each of the SRB genes was deleted to produce srb4Δ2, srb5Δl, and srb6Δl. SRB4 and SRB6 are essential. SRB5, like SRB2, is not essential, but cells lacking the gene exhibit the slow -16growth, cold-sensitive, and temperature-sensitive phenotypes characteristic of CTD truncations. SRB2 and SRB5 Are Required for Efficient Transcription In Vitro Although yeast cells lacking SRB4 or SRB6 are not viable, cells lacking SRB2 or SRB5 are viable despite striking defects in growth, and it is this feature that facilitates investigation of the transcriptional activity of SRB2 and SRB5 proteins using nuclear extracts in vitro. Previous studies had revealed that SRB2 is required for efficient basal and activated transcription initiation in vitro. The role of SRB5 was investigated similarly and was also found to be required for efficient basal and activated transcription initiation in vi tro as described in Example 2 (See Figure 3A) . Nuclear extracts were prepared from wild-type and srb5Δl cells and tested for their ability to synthesize a specific transcript in the presence and absence of purified recombinant SRB5 and GAL4-VP16 proteins. Extracts from wild-type cells produced two specific transcripts of 375 and 350 nt, and the addition of GAL4-VP16 produced a 35-fold in¬ crease in the levels of these transcripts. Extracts from srb5Δl cells required additional factors in order to synthesize significant levels of specific transcripts, in both the presence and the absence of GAL4-VP16 (Figures 3B and 3C) . Complementation of the srb5Δl extract required both purified recombinant SRB2 and SRB5; the addition of SRB5 alone failed to complement. Western blot analysis revealed that the level of SRB2 protein is greatly reduced in extracts prepared from srb5Δl cells. To confirm and extend these results additional transcription assays were performed using nuclear extracts prepared from cells lacking SRB2 and SRB5 (Figures 3D and 3E) . The results obtained using extracts from cells lacking both SRB proteins were identical to those obtained with extracts from srb5Δl cells. These extracts exhibited no defects in promoter-independent transcription elongation assays. These results indicate that both SRB2 and SRB5 are required for efficient basal and activated transcription initiation in vi tro. Formation of a Stable Preinitiation Complex Involves SRB2 and SRB5 A template commitment assay was used to investigate whether both SRB2 and SRB5 participate in the formation of a transcription initiation complex (Figure 4A and 4B) . Extracts prepared from cells lacking SRB2 and SRB5 were used for performing this assay. Two templates were employed that contained identical promoters but differed in G-less cassette length. Specific transcripts of 375 and 350 nt were produced from the long template, while transcripts of 275 and 250 nt were produced from the short template. An experiment was first performed to confirm that SRB2 is required for efficient formation of a stable preinitiation complex (Figure 4A) , as described above. The two templates were incubated separately with nuclear extract and SRB5, and a limiting amount of SRB2 protein was added to 1 of the 2 reaction mixtures. After a 60 min preincubation, the 2 reactions were mixed together. Immediately after mixing and every 10 min thereafter, aliquots were removed and nucleotide triphosphates were added to permit RNA synthesis. The reaction was stopped after 7 min to minimize multiple rounds of transcription. Control experiments are shown in lanes 1-4. When srb2Δl, srbδΔl extracts were preincubated with SRB2 and SRB5 along with either the long template (Figure 4A, lane 1) or short template (Figure 4A, lane 2) , transcripts of the predicted size were produced. When both long and short templates were present in the preincubation mixture, similar levels of long and short transcripts were obtained (Figure 4A, lane 3) . Virtually no transcript was detected when both templates were preincubated with the extract in the presence of SRB5 alone (Figure 4A, lane 4) . When SRB2 was added to the long template mixture, long transcripts were predominant after the two extracts were mixed (Figure 4A, lanes 5-8) . There was no appreciable increase in signal from the short template after 30 min of mixing with the long template. Similarly, when SRB2 was added to the short template mixture, transcripts were produced predominantly from the short template with no appreciable increase in signal from the long template after 30 min of mixing (Figure 4A, lanes 9-12) . To determine whether SRB5 is required for efficient preinitiation complex formation, a similar experiment was performed (Figure 4B) . -This time, the two templates were incubated separately with extract and SRB2, and a limiting amount of SRB5 was added to 1 of the 2 reaction mixtures. The remaining steps were performed as described above. The results of the controls (Figure 4B, lanes 1-4) were identical to those in Figure 4A. Lanes 5-12 in Figure 4B show that transcripts were predominantly obtained from the template that was preincubated in the presence of SRB5 and that there was no significant increase in signal, even after 30 min, from the template incubated in the absence of SRB5. The template commitment assay results indicate that both SRB2 and SRB5 are required for formation of a stable preinitiation complex and that SRB2 and SRB5 act stoichiometrically in the initiation reaction. These conclusions are based upon two observations. First, the template preincubated in the presence of all necessary factors was preferentially transcribed, upon mixing, relative to the other template, which was incubated in the absence of either SRB2 or SRB5. Second, following mixing, there was no appreciable increase in signal from the template incubated in the absence of either SRB2 or SRB5. If SRB2 or SRB5 acted subsequent to initiation, the templates would be transcribed equally well; since up to 30 min of incuba¬ tion was allowed after template mixing, there was ample time for any catalytic activity to be carried out on the second template. The observation of little to no increase in second template transcription, even after 30 min, indicates that SRB2 and SRB5 became stably associated with the first template during preincubation. When the experiment in Figure 4A was performed using excess SRB2 in the preinitiation step, transcription increased with time from the template that was preincubated in the absence of SRB2. Similarly, when the experiment in Figure 4B was performed using excess SRB5 in the preincubation step, transcription increased with time from the template that was preincubated in the absence of SRBS. This indicates that much of the template that was preincubated in the absence of SRB2 or SRB5 was still available for transcription and that SRB2 and SRB5 continued to be active for an extended period in the reaction mixture. These data suggest that SRB2 and SRB5 are integral components of the preinitiation complex. SRB Proteins, TBP, and RNA Polymerase Are Components of a 1.2 Md Complex The ability of mutations in SRB2, SRB4, SRB5, and SRB6 to specifically suppress the growth phenotypes of cells with CTD truncations indicates that the products of these genes are involved in the same functional process as the CTD. Template commitment assays suggest that SRB2 and SRB5 are components of the transcription initiation complex. These functional studies led to the investigation of whether the SRB proteins interact physically with one another. Cells were constructed that produce functional, epitope-tagged SRB4, SRB5, or SRB6 proteins, and transcriptionally competent nuclear extracts were prepared from these cells. When SRB4, SRB5, or SRB6 were immunoprecipitated, SRB2 and 5%-10% of the TBP in the extract were coprecipitated, as revealed by immunoblotting. This observation suggested that the four SRB proteins and TBP are components of a multisubunit complex which led to an attempt of purification of the SRB proteins from wild-type cells by conventional chromatography. Whole-cell extracts from wild-type cells were fractionated through a series of seven chromatography columns, and rabbit polyclonal antibodies generated against recombinant SRB2, SRB4, SRB5, and SRB6 and against recombinant TBP were used to monitor these proteins during purification (Figure 5A) . Essentially all of the SRB2, SRB4, SRB5, and SRB6 in the whole-cell extract cofractionated through the seven purification steps. Approximately 20 additional polypeptides, including a portion of the TBP in the extract, cofractionated with the four SRB proteins. A subset of these additional polypeptides was identified as RNA polymerase II subunits by Western blot analysis. The high molecular weight complex containing TBP, SRB proteins and RNA polymerase II appeared to be quite stable. The proteins in this complex remained tightly associated in fractions exposed to a variety of strong ion exchangers at salt concentrations up to 1.1 M potassium acetate and upon gel filtration in buffers containing 400 mM potassium acetate. Figure 5C shows, for example, the elution profile of TBP, SRB proteins, and RNA polymerase II from the Mono S column. It is estimated that the complex was purified approximately 10,000-fold by quantitative Western blot analysis. The complex appeared to be purified to near homogeneity, since the composition of the complex did not change on chromatography subsequent to the Mono S column. Gel filtration on Superose 6 revealed that these approximately two dozen polypeptides comigrate as a complex at a position corresponding to a native molecular mass of about 1.2 Md. The sum of the apparent molecular weights of the polypeptide bands that appear to be components of the complex is 1.4 Md, consistent with the size predicted by gel filtration. Since RNA polymerase II accounts for approximately 0.5 Md, the remaining complex has a mass of 0.7-0.9 Md. The components of the 1.2 Md complex have both SRB and RNA polymerase activities in vi tro. The 1.2 Md complex can complement a nuclear extract lacking SRB2 and SRB5. The specific activity of native SRB2 and SRB5 in the complex was 100-fold that of recombinant SRB2 and SRB5 proteins In this assay. The RNA polymerase activity of the complex is comparable to that obtained with similar amounts of the purified enzyme in nonspecific transcription assays. A CTD Column Specifically Retains a TBP-Containing Multisubunit Complex The presence of RNA polymerase II and SRB proteins in a TBP-containing multisubunit complex, together with evidence that the CTD interacts with TBP suggested that the SRB-TBP complex may physically interact with RNA polymerase II via the CTD. To investigate this possibility, yeast whole-cell extract was loaded onto columns containing recombinant glutathione S-transferase (GST) -CTD fusion protein or GST alone. The columns were washed extensively, and bound protein was eluted with low concentrations of guanidine hydro¬ chloride. Guanidine hydrochloride (0.3 M) was used for elution because proteins specifically bound to the GST-CTD column could not be eluted with buffers containing high salt concentrations (2 M potassium ace¬ tate) . The proteins that specifically bound the GST-CTD affinity column include the four SRB polypeptides, TBP, and at least a dozen additional polypeptides. Many of these proteins appear to be components of the TBP-containing multisubunit complex purified by conventional chromatography. The RNA Polymerase II Holoenzyme Is Responsive to Activators The SRB proteins, which play essential roles in transcription initiation in vivo and in vi tro, copurify with RNA polymerase II and additional unidentified polypeptides in a high molecular weight complex. To further investigate the role of the RNA polymerase II- containing complex in transcription initiation, a search was made for additional components needed for selective transcription in vi tro . The RNA polymerase II holoenzyme and factor a were purified as described in Example 2, and as described in Sayre, M.H., et al., J. Biol. Chem. 267:23383-23387 (1992). Because the complex contains similar amounts of RNA polymerase II and SRB protein molecules, but substoichiometric amounts of TBP, TBP levels needed to be supplemented to support in vi tro transcription. (See Example 3) . Specific transcription of promoter-containing DNA was obtained following the addition of recombinant TBP and a fraction from a yeast whole cell extract to the RNA polymerase II-containing complex. Purification of this activity revealed that it is composed of two polypeptides whose chromatographic behavior and size (66 kD and 43 kD) are identical to that described for factor a, the yeast homologue of TFIIE. Thus, the RNA polymerase II-containing complex represents a novel form of the enzyme that is capable of site-specific initiation when supplemented with yeast TBP and transcription factor a. Since purified RNA polymerase II requires the assistance of multiple general transcription factors for selective transcription initiation, these results suggested that the high molecular weight RNA polymerase II complex might contain some of these general factors preassembled into the complex, producing an RNA polymerase II holoenzyme. It was further investigated whether a subset of the general transcription factors are associated with RNA polymerase II and SRB proteins in the high molecular weight complex. The general transcription factors bind to common promoter elements such as TATA or initiation motifs. These protein factors include, but are not limited to, TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIG and TFIIH. Five general factors (a, b, d, e, and g) are sufficient to allow yeast RNA polymerase II to accurately initiate transcription in vitro. Column fractions from the final purification step of the RNA polymerase II holoenzyme were tested in recon¬ stituted transcription reactions and subjected to western blot analysis with antisera specific to yeast initiation factors (Figure 6A) . Transcription activity coeluted with RNA polymerase II and the SRB2, SRB4, SRB5, and SRB6 proteins. The activity also coeluted with the 41 Kd yeast factor e (TFIIB) protein and the 73 kD TFB1 subunit of yeast factor b (TFIIH) . Although specific antisera are not yet available for factor g (TFIIF) , the purified complex (Figure 6B) contains 3 polypeptides whose sizes coincide with those reported for subunits of purified factor g (105, 55, and 30 Kd) . Furthermore, TFIIF and TFIIH are essential for the transcription of linear templates by human RNA polymerase II, and it was found that the RNA polymerase II holoenzyme can transcribe linear templates, supporting the inference that the holoenzyme contains activities homologous to TFIIF and TFIIH. Taken together, these results indicate that the purified complex represents a form of RNA polymerase II that is tightly associated with multiple SRB proteins and with factors b, e, and g (TFIIH, TFIIB, and TFIIF), and that this form of RNA polymerase II holoenzyme can accu¬ rately initiate transcription when supplemented with factor a (TFIIE) and TBP. The RNA polymerase II holoenzyme is a highly stable complex; it remains intact upon chromatography through six ion exchange columns and migrates as a single 1.2 Md complex upon gel filtration. To confirm that the holoenzyme consists of a single multisubunit complex, immunoprecipitation experiments were performed. The four SRB proteins, factor e (TFIIB) , the TFB1 subunit of factor b (TFIIH) , and RNA polymerase II were all found to specifically coimmunoprecipitate from purified preparations of the RNA polymerase II holoenzyme using anti-SRB5 antibodies (Figure 6C) . Similar results were obtained when the complex was immunoprecipitated with antibodies against other holoenzyme components. The holoenzyme preparation contains approximately equimolar amounts of SRB2, SRB5, factor e (TFIIB) and RNA polymerase II (Figure 6D and 6E) . The highly purified holoenzyme does not contain significant amounts of TBP or the TOA1 subunit of yeast TFIIA (Figure 6D) . Although previously shown that some TBP is associated with the multisubunit complex, the highly purified holoenzyme contains less than one molecule of TBP per fifty molecules of RNA polymerase II, consistent with the observation that transcription by the holoenzyme is absolutely dependent on the addition of purified recombinant TBP. At each step in the purification of the holoenzyme, a portion of TBP coelutes from the column with the holoenzyme, while a portion of the TBP elutes as free TBP. This behavior may reflect a weak interaction of TBP with the holoenzyme complex in the absence of DNA, as the purified holoenzyme contains no detectable DNA. TBP can bind to SRB2, SRB5, and the RNA polymerase II CTD on affinity columns, suggesting that TBP may interact physically with these components of the holoenzyme. The ability of the RNA polymerase II holoenzyme to respond to transcriptional activators was also investigated. Purified yeast RNA polymerase II and general transcription factors alone are unable to respond to transcriptional activators. Transcription of supercoiled templates could be stimulated 5-fold by the transcriptional activator GAL4-VP16 in reactions reconstituted with the RNA polymerase holoenzyme, TBP, and factor a (Figure 7A) . Similar results were obtained when linearized templates were used for in vi tro transcription (Figure 7B) . For comparison, GAL4-VP16 stimulated transcription of a supercoiled template in crude yeast nuclear extracts 10-fold under the same conditions (Figure 7A) . These data indicate that one or more components of the holoenzyme are able to respond to activation signals from GAL4-VP16. The presence of an RNA polymerase II holoenzyme probably escaped earlier detection because of its low abundance relative to free RNA polymerase II. While most of the SRB protein in whole cell extracts is co plexed with RNA polymerase II, only 6% of RNA polymerase II and 12% of TFIIB is found in the holoenzyme. The nuclear RNA polymerases were originally purified using nonspecific transcription assays, and the general factors that are necessary to direct selective initiation by the purified enzymes were subsequently identified. In contrast, the discovery of a holoenzyme began with a genetic search for factors involved in RNA polymerase 11 transcription in vivo. The genetic experiments demonstrated a physiological role for the SRB proteins in transcrip¬ tion by RNA polymerase in vivo. The biochemical analysis revealed that the SRB proteins are essential transcription initiation factors, and that most of the SRB protein in cells is contained within the holoenzyme. It is estimated that yeast haploid cells contain approximately 1000 molecules of the holoenzyme, adequate amounts to initiate transcription at active promoters. However, the proportion of active promoters that are transcribed by the holoenzyme is not yet known. It is possible that the holoenzyme is preferentially utilized at some promoters, while free RNA polymerase II and general factors are recruited in a stepwise fashion to others. A significant fraction of cellular RNA polymerase II is involved in elongation of nascent transcripts, and accounts for at least a portion of the enzyme that is not complexed with SRB proteins. The existence of an RNA polymerase II holoenzyme preassembled with a subset of general initiation factors has implications for the mechanisms involved in the regulation of transcription. Activators appear to function, at least in part, through interactions with multisubunit TFIID. The holoenzyme may be efficiently recruited to promoters through interactions with gene activators and promoter-bound TFIID. The level of activation in crude extracts is more than two-fold greater than the level of activation obtained with the purified holoenzyme. This difference may reflect the absence of TAFs in the reactions reconstituted with the holoenzyme.. Suppressors of RNA Polymerase II CTD Truncation Mutations Extragenic suppressors of a Saccharomyces cerevisiae RNA polymerase II CTD truncation mutant were isolated to identify additional components of the transcription apparatus that affect CTD function. (Figure 8) . The cold-sensitive phenotype of cells containing RNA polymerase II CTDs with only 11 intact heptapeptide repeats (rpblΔl04) was exploited to obtain 81 independent suppressing isolates, of which approximately one third were dominant and two-thirds recessive. Genetic analysis has revealed that mutations in at least ten genes will suppress growth defects of cells containing a truncated CTD. As described above, dominant mutations have been found in four genes, designated SRB2, SRB4, SRB5, and SRB6. Using genetic and molecular complementation analysis, recessive suppressing mutations in six additional genes: SRB7, SRB8, SRB9, SRBIO, SRB11, and RPB2 have been identified. Recessive suppressing alleles of SRB4 and SRB6 were also identified. This selection appears to be nearly saturated since, with the exception of SRB11, more than one independent isolate of each of the ten genes has been identified. The characterization and cloning of the genes containing recessive suppressing mutations is presented in Example 4. SRB7, SRB8, SRB9, SRBIO and SRB11 are newly identified genes, whereas RPB2 is the gene encoding the second largest subunit of RNA polymerase II. Genetic Analysis of SRB7. SRB8. SRB9. and RPB2 The ability of suppressing alleles of SRB7, SRB8 SRB9, and RPB2 (srb7-l, srb8-l, srb9-l and rpb2-551, respectively) to suppress conditional phenotypes associated with the CTD truncation mutation rpblΔl04 was further investigated. These phenotypes include cold- and temperature-sensitive growth and the inability to utilize pyruvate as a carbon source. Growth phenotypes of cells containing an RPBl CTD truncation mutation and srb7-l, srb8-l, srb9-l, or rpb2-551. Cells were spotted on YEPD medium and incubated at 12°C, 30°C and 38°C and on SC medium containing pyruvate as a sole carbon source. Isogonic wild-type, srb7-l, srb8-l, srb9-l, and rpb2-551 backgrounds contained either wild-type RPBl (27 repeat CTD) or rpblΔl04 (11 repeat CTD) . The srb7-l, srb8-l, srb9-l, or rpb2-551 alleles permit growth of rpblΔl04 cells at 12°C and on media containing pyruvate as a sole carbon source. Cells containing these suppressing alleles, however, do not suppress the temperature-sensitivity associated with the CTD truncation mutation. These srb and rpb2 alleles do not suppress the conditional phenotypes of other mutations in RPBl that have been tested. This specificity of suppression argues that SRB7, SRB8, SRB9, RPB2, and the CTD are involved in the same process in transcription initiation. Cloning and Seguence Analysis of SRB7. SRB8, SRB9. and RPB2 Genomic DNA clones containing SRB7, SRB8, SRB9, and RPB2 were isolated by exploiting their ability to reverse the suppressing phenotype of the recessive srb or rpb2 alleles. A wild-type genomic DNA library constructed in a yeast URA3 centromeric plasmid was transformed into yeast cells containing the CTD truncation mutation rpblΔl04 and srb7-l, srb8-l, srb9-l, or rpb2-551. Ura + transformants were then screened for lack of growth at 12°C and on pyruvate media. When necessary, the wild-type genes were further localized by subcloning fragments of the genomic inserts and again screening Ura + transformants unable to grow at 12°C and on pyruvate media. The clones with the smallest inserts were sequenced. The predicted SRB7 protein is 140 amino acids long (SEQ ID NO: 10) and has a molecular mass of 16 Kd (Figure 9) . SRB8 is predicted to be 1226 amino acids in length (SEQ ID NO: 12) with a molecular mass of 144 Kd (Figure 10A and 10B) . Partial sequence analysis of SRB8 revealed that it is ORF YCR81W (Oliver, S. G. , et al., Nature 357:38-46 (1992)). The predicted SRB9 protein is 1420 amino acids long (SEQ ID NO: 11) and has a molecular mass of 160 Kd (Figure 11A, 11B and 11C) . Partial sequence analysis of the fourth clone identified RPB2 as a suppressor of CTD truncations. A search of the sequence data banks revealed that SRB7, SRB8, and SRB9 do not have significant sequence similarity to previously identified proteins. SRB9 does, however, contain a single polyglutamine stretch of 16 residues from amino acids 1121 to 1136. The DNA sequences and predicted amino acid sequences for SRBIO (SEQ ID NO: 15 and 16) and SRB11 (SEQ ID NO: 17 and 18) are shown in Figure 12 and Figure 13, respectively. SRB7 and SRB9 were physically mapped using the prime λ, clone grid filters of the yeast genome (provided by L. Riles and M. Olson, Washington University) . SRB7 maps to the right arm of chromosome IV, approximately 45 kb centromere distal to GCN2 (λ clone 6118) . SRB9 also maps to the right arm of chromosome IV, approximately 35 kb centromere distal to ADE8 (λ clone 5513) . SRB8 maps to the right arm of chromosome III, approximately 5 kb centromere proximal to TUP1. The srb7-l and rpb2-551 mutant alleles were obtained by plasmid gap repair in vivo. Plasmids containing these mutant alleles did not prevent growth at 12°C, unlike their wild-type counterparts, when transformed into yeast cells containing the CTD truncation mutation rpblΔl04 and srb7-l or rpb2-551, respectively. This confirms that in each case the correct locus was cloned. The identification of the correct open reading frame is further supported by identification of the suppressing mutations of srb7-l and rpb2-551, identified by comparing the complete sequences of the cloned wild-type and suppressing alleles. In each case, the alterations were single-point, missense mutations. The mutation in srb7-l changes alanine 21 to threonine. The rpb2-551 mutation changes alanine 1200 to valine. SRB8 and SRB9 are Negative Regulators of CTD Function To determine whether the SRB genes are essential for cell viability, most, if not the entire coding region of each of the SRB genes was deleted to produce srb7Δl, srb8Δl, and srb9Δl. SRB7, like RPB2, is essential. SRB8 and SRB9 are not essential, but cells lacking either one of these genes flocculate and exhibit mild cold- and temperature-sensitive phenotypes. Significantly, null alleles of SRB8 and SRB9 partially suppress the conditional phenotypes associated with CTD truncations. Phenotypes exhibited by deletions of SRB8 or SRB9 are very similar to those phenotypes exhibited by the suppressing mutant alleles of these genes, indicating that we have cloned and identified the correct gene. The influence of srbδΔl and srb9Δl on RNA polymerase II CTD function was further investigated by examining the effect of these deletion alleles on the growth phenotypes of cells containing a spectrum of CTD truncation mutations. Yeast cells lacking SRB8 partially suppressed the conditional phenotypes associated with CTD truncations containing 10-12 complete heptapeptide repeats. Moreover, the lack of SRB8 allowed cells with only nine heptapeptide repeats to survive; thus, loss of SRB8 counters the defects associated with CTD truncation. This pattern of suppression is opposite to that observed with SRB2 alleles. The dominant, gain-of-function SRB2-1 allele produces the same suppression phenotype as the recessive, loss-of-function srb8Δl allele. In contrast, the recessive, loss-of-function srb2Δl allele, increases the severity of the defects associated with CTD truncation. The influence of srb9Δl on the phenotypes of cells containing CTD truncations is similar to that of srbδΔl. SRB8 and SRB9, therefore, behave as negative regulators of CTD function, while SRB2 behaves as a positive regulator of CTD function. SRB7, SRB8, and SRB9 are Components of an RNA Polymerase II Holoenzyme It was investigated whether SRB7, SRB8, and SRB9 are also components of a RNA Polymerase II holoenzyme. Rabbit polyclonal antibodies were generated against recombinant SRB7, SRB8, and SRB9. Column fractions from the final purification step of the RNA polymerase II holoenzyme were tested in reconstituted transcription reactions and subject to Western blot analysis with antisera specific to RNA polymerase II and SRB proteins (Figure 15A and 15B) . Transcription activity coeluted with RNA polymerase II and the SRB2, SRB4, SRB5, SRB6, SRB7, SRB8, and SRB9 proteins. Multiple Factors Influence CTD Activity In order to better define the role of the CTD of RNA polymerase II in transcription initiation, extragenic suppressors of a CTD truncation mutant have been isolated Ten genes, SRB2, SRB4-SRB11, and RPB2, have now been identified in this selection. The observation that the suppressing mutations in these genes suppress the conditional and auxotrophic phenotypes associated with CTD truncations, but not similar phenotypes associated with point mutations outside of the CTD, argues that these gene products and the CTD are involved in the same process in transcription initiation. Genomic DNA for the genes identified in this selection has been cloned and sequenced. These SRB factors are necessary for yeast cells to grow at wild-type rates and for survival throughout the normal temperature range for cell growth (See Table 1) . Table 1. SRB enes a precise map locations have been determined b null alleles partially suppress conditional phenotypes associated with CTD truncations 1) Nonet and Young 1989, 2) Koleske et al. 1992, 3) Thompson et al . 1993, 4) Koleske and Young 1994, 5) Sweetser et al . 1987 SRB genes encode positive and negative regulators of CTD function. Dominant, gain-of-function mutations in SRB2 and SRB5 suppress CTD truncation mutations. Furthermore, cells lacking SRB2 can survive only if the CTD is nearly wild-type in length. In contrast, it is the absence of SRB8 or SRB9 which suppress CTD truncation mutations. SRB8 and SRB9 proteins, therefore, appear to repress CTD activity while SRB2 and SRB5 proteins enhance CTD activity. Figure 16 depicts the RNA Polymerase II holoenzyme model for assembly into an initiation complex. Multiple interactions between components of the holoenzyme, activator proteins and transcription factor TFIID facilitate stable initiation-complex formation. The SRBs may influence the stability of the holoenzyme or the recruitment of the holoenzyme into a preinitiation complex, possibly in response to regulatory factors. The RNA Polymerase II Holoenzyme Is The Predominant Form Of The Enzyme In The Cell Recruited to Promoters A set of experiments were performed to demonstrate a general requirement for the SRBs in RNA polymerase II transcription in vivo . These data suggest that the RNA polymerase II holoenzyme is the predominant form of the enzyme recruited to promoters in the cell. A PCR-based mutagenesis strategy was used to construct a mutagenized library of the SRB4 gene and plasmid shuffle techniques were then used to identify a recessive ts allele, srb4-138. The effect of the srb4- 138 mutation on cell growth was investigated. Mutant cells grew normally at the permissive temperature of 30°C but failed to grow at the restrictive temperature of 37°C. Upon shifting a growing culture of srb4-138 cells to the restrictive temperature, growth rapidly decreased, failing to double before growth ceased altogether. Sequence analysis of srb4-138 revealed multiple point mutations in the open reading frame. The mutation causing the ts phenotype was not determined. The effect of the srb4-138 mutation on mRNA synthesis was investigated by growing wild-type and mutant cells at the permissive temperature, then shifting the cultures to the restrictive temperature. Aliquots were taken immediately before and at various times after the shift and total RNA was prepared. The amount of poly(A) + mRNA for each sample was determined by slot blot analysis. Equal amounts of total RNA were blotted and probed with labeled poly(T) . Following the shift to the restrictive temperature there is a dramatic and rapid decline in mRNA in mutant cells while wild-type cells are largely unaffected, indicating a general defect in RNA polymerase II transcription at the restrictive temperature in srb4- 138 cells. To investigate the defect in RNA polymerase II transcription in more detail, synthesis of specific mRNAs was investigated. Equal amounts of total RNA prepared from each sample were hybridized with an excess of labeled complementary oligonucleotide to the ACT1, CDC7, DED1, HIS3, MET19, RAD23, STE2, TCM1, and TRP3 transcripts, and the resulting products were treated with SI nuclease and subjected to denaturing polyacrylamide gel electrophoresis. These nine messages represent a broad spectrum of genes affecting diverse cellular processes. Since this approach measures steady-state levels of mRNAs, in the absence of new mRNA synthesis, the rate of reduction is a function of mRNA decay rate. All nine of these messages are sensitive to loss of SRB4 activity. Wild- type cells, on the other hand, continue to synthesize these transcripts throughout the entire 4-hour period at 37°C. The transient decrease in the levels of some of the transcripts from wild-type cells is due to a mild heat shock response (Nicolet, CM. and Craig, E.A., Meth. Enzvmol. 194:710 (1991)). The influence of the srb4-138 mutation on tRNA synthesis by RNA polymerase III was also investigated. tRNAs are extremely stable, but their transcripts contain introns which are rapidly processed with half- lives of less than 3 minutes (Cormack B.P., and Struhl, K. Cell 69:685 (1992); Knapp, G. et al . , Cell 14:221 (1978)). SI nuclease analysis with an oligonucleotide complementary to the 5' intron-exon junction of the tryptophan family of tRNA transcripts was used to measure RNA polymerase III activity. There is no appreciable effect on the RNA polymerase III synthesis of tRNA by the srb4-138 mutant. rRNA synthesis by RNA polymerase I was similarly investigated using Si nuclease analysis with an oligonucleotide complimentary to the 3' processing junction of the short lived ribosomal precursor RNA (Cormack B.P., and Struhl, K. Cell 69:685 (1992); Ke pers-Veenstra, A.E. et al. , EMBO J. 5:2703 (1986)). There is a substantial decrease in synthesis of the precursor rRNA transcript in the srb4-138 mutant. This decrease in RNA polymerase I activity is similar to that observed in cells containing the ts rpbl-1 allele of RPBl, the gene encoding the largest subunit of RNA polymerase II. (Cormack B.P., and Struhl, K. Cell 69:685 (1992); (Nonet, M. et al. , Mol. Cell. Biol. 7:1602 (1987)). RNA polymerases II and III activities in srb4-138 and rpbl-1 cells are also nearly identical. At the restrictive temperature the synthesis of MET19 and RAD23 transcripts is dramatically reduced while the synthesis of tRNA is largely unaffected. The shutdown of rRNA synthesis in rpbl-1 and srb4-138 cells may be a consequence of a stringent response that shuts off rRNA synthesis under conditions when gene expression is affected (Nonet, M. et al. , Mol. Cell. Biol. 7:1602 (1987) ) . The general cessation of mRNA synthesis in srb4- 138 cells is unlikely due to indirect effects of metabolic mayhem at 37°C or loss of a highly unstable protein that is encoded by an unstable RNA whose synthesis is dependent on SRB4. Similar temperature- shift experiments conducted by Cormack, B.P. and Struhl, K. (Cell 69:685 (1992)) using a strain containing a ts mutation in CDC28, the gene encoding the cyclin-associated protein kinase that mediates entry into the cell cycle, showed no appreciable effects on RNA polymerase II transcription. In the same study these investigators examined the effects of cycloheximide, a potent inhibitor of cellular translation, on transcription of a subset of messages in wild-type cells and found no effect on the synthesis of these transcripts. It was previously estimated that approximately 6% of the RNA polymerase II in the cell was in the holoenzyme, adequate amounts to initiate transcription at active promoters. It was unclear, however, if the holoenzyme was preferentially recruited to some promoters, while free RNA polymerase II and general factors were recruited in a step-wise fashion to others. It appears now that the holoenzyme is the form of RNA polymerase II utilized at most promoters. This conclusion is based upon the above demonstration that SRB4 plays a general role in RNA polymerase II transcription and that the majority of SRB4 in the cell is tightly associated with RNA polymerase II in the holoenzyme. These results have important implications for the regulation of transcription initiation. A fraction of RNA polymerase II is involved in elongation of nascent transcripts, accounting for at least some of the enzyme not complexed with SRB proteins. Thus, remaining RNA polymerase II and general factors would be competing for limited amounts of SRBs. The SRBs, therefore, can play a key regulatory role in RNA polymerase holoenzyme formation leading to initiation complex assembly. Mammalian RNA Polymerase II Holoenzyme Complex The XREFdb service was used to identify three overlapping expressed sequence tags homologous to yeast SRB7 as described in Example 6. hSRB7, a human homolog of yeast SRB7, was cloned and sequenced using sequence information derived from the expressed sequence tags. hSRB7 encodes a 144 amino acid protein with a predicted molecular weight of 15.7 kD (SEQ ID NOs: 36 and 37 as shown in Figure 17A). It is 35% identical and 58% similar to its yeast counterpart. Homology searches indicate that yeast and human SRB7 are more similar to each other than to any other sequenced gene (Figure 17B) . There is a restriction length polymorphism at position 627 (numbering from the beginning of the DNA sequence) of the hSRB7 cDNA. In some individuals, the sequence is GATC; in other individuals the sequence is GATT. GATC is the restriction site for the enzyme Sau3A. This polymorphism is useful for determining the linkage of locii to the hSRB7 gene. For instance, one could use the polymorphism to determining if a genetic disease is caused by mutation in hSRB7. Because of the high degree of conservation between the yeast and human genes, it was decided to test whether hSRB7 could functionally complement (e.g., was functionally equivalent to) a yeast SRB7 deletion mutant. Initial results indicated that full length hSRB7 was unable to complement the yeast deletion. Because the most conserved regions of SRB7 are found on its N-terminal end, it was hypothesized that chimeras containing the N-terminus from the human gene and the C-terminus of the yeast gene would be functional. A panel of chimeras was constructed and tested for their ability to complement the yeast SRB7 deletion as described in Example 7. It was found that several hSRB7-ySRB7 chimeras fully complemented the ySRB7 deletion. The chimera containing the largest amount of hSRB7 contains 117 amino acids from the N-terminus of the human gene and only 12 from the C-terminus of the yeast gene. This data presents additional support that hSRB7 is the human counterpart of ySRB7, not only by sequence homology, but also by a functional test. Corroborating biochemical evidence was obtained to supplement the genetic evidence that hSRB7 is a genuine homolog of ySRB7. A distinctive biochemical property of the yeast SRBs is their ability to bind specifically to the CTD. Several yeast SRBs form a complex that can be isolated by CTD affinity chromatography, therefore it was suspected that yeast SRB7 would also bind to the CTD. Analysis of eluates from control and CTD affinity columns confirmed this hypothesis. Like other SRBs, ySRB7 was specifically retained by a CTD column. A similar experiment was performed with hSRB7. First, antisera directed against hSRB7 was prepared and characterized, as described in Example 8. This antisera recognizes 16 kD bands in HeLa and calf thymus extracts which represent human and bovine SRB7, respectively. This antisera was then used to probe Western blots of eluates from CTD-affinity and control columns. Mammalian SRB7 derived from both HeLa cells and calf thymus binds specifically to the CTD indicating that hSRB7 and yeast SRB7 not only have similar amino acid sequences and functions in vivo, but also share the ability to bind specifically the CTD. Based on the criteria of sequence similarity, functional complementation and CTD-binding, it is reasonable to conclude that hSRB7 is a bona fide human homolog of ySRB7. In yeast, SRB proteins are the hallmarks of the RNA polymerase II holoenzyme. Given the homology between ySRB7 and hSRB7, is was hypothesized that hSRB7 would be part of a similar holoenzyme complex in mammalian cells. To test this hypothesis, it was determined whether hSRB7 is associated with RNA polymerase II or other basal transcription factors. hSRB7 and its associated proteins were precipitated with an anti-hSRB7 peptide antibody and analyzed as described in Example 9. Western blots indicate that the anti-hSRB7 immunoprecipitates contain pol II and hSRB7. This interaction is specific because a control immunoprecipitate with peptide blocked antibody does not contain detectable pol II or hSRB7. Because of interference from the antibody heavy and light chains, it was not possible to use Western blots to assay for the presence of other general factors. As an alternative, in vi tro transcription assays were used. These transcriptional assays indicate that the anti-hSRB7 immunoprecipitates contain not only RNA polymerase II activity but also TFIIE and TFIIH activities. It is reasonable to conclude from these results that hSRB7 specifically associates with RNA polymerase II, TFIIE and TFIIH. The mammalian RNA polymerase II holoenzyme was purified from calf thymus by assaying for the presence of SRB proteins. The progress of the purification procedure with monitored by Western blot analysis with anti-hSRB7 antibody. SRB7 and associated proteins were purified from calf thymus over six ion exchange columns. Mammalian SRB7 coelutes precisely with the RNA polymerase II largest subunit throughout the purification procedure. Silver-staining of the most highly purified fraction suggests that the complex containing SRB7 and RNA polymerase II contains approximately thirty polypeptides. To confirm these results the holoenzyme was purified using a different procedure. Mammalian SRB7 and RNA polymerase II coelute precisely throughout the purification procedure and, again, the same coeluting polypeptides are evident. It is estimated that SRB7 is associated with at least 20% of the RNA polymerase II that is extracted from calf thymus cells. The purification procedure removed approximately 80% of the RNA polymerase II present in the crude extract before SRB7 could be assayed reliably. Once SRB7 could be reliably detected, the remaining 20% of RNA polymerase II was always observed to cofractionate with SRB7. The transcriptional activity of the purified holoenzyme was analyzed in vi tro as described in Example 10. The template for the reactions contains the adenovirus major late promoter which stringently requires RNA polymerase II, TBP, TFIIB, TFIIF, TFIIE, and TFIIH when in a linear form. In reactions containing column-purified holoenzyme as the source of RNA polymerase II and the other five basal factors, specific transcription from the major late promoter was observed. When the holoenzyme was omitted but the other five factors were included, no RNA product was detected, consistent with the requirement for RNA polymerase. Longer exposure of autoradiograms indicates that omission of TBP, TFIIB, TFIIE or TFIIH resulted in low but significant levels of transcription. These results demonstrate that the holoenzyme is capable of transcription in vitro when supplemented with basal transcription factors and suggest that trace amounts of other basal factors are presented in the purified holoenzyme preparation. A feature of the yeast holoenzyme is its responsiveness to stimulation by an acidic activating protein in vitro. The response of the purified mammalian holoenzyme to an activator was investigated using two templates containing either the adenovirus major late promoter or the same promoter with upstream binding sites for Gal4. With highly purified transcription factors and core RNA polymerase II, inclusion of Gal4-VP16 had no effect unless the coactivators HMG-2 and PC4 were present, in which case only two-fold activation was observed. In contrast, when the holoenzyme was included in place of core RNA polymerase II, coactivators were still required for activation, but the specific activation by Gal4-VP16 increased to approximately five-fold. All of the RNA polymerase II holoenzymes that have been descx*ibed so far contain RNA polymerase II and SRBs. However, different forms of holoenzyme contain different subsets of the general transcription factors. The mammalian holoenzyme described herein contains RNA polymerase II, hSRB7 and is associated with TFIIE, TFIIH. One form of yeast holoenzyme contains RNA polymerase II, SRBs, and is associated with TFIIB, TFIIF, and TFIIH. Other forms of the yeast holoenzyme have the same factors except for TFIIB, TFIIH or both. One explanation for the observed differences is that multiple forms of holoenzyme complex exist in vivo. It is possible that the RNA polymerase II holoenzyme may associate with different subunits during the transcription cycle. For instance, during the transcription cycle, there may be a form of the holoenzyme involved in transcription initiation which is then converted to a form involved in elongation. It is also possible that the RNA polymerase II holoenzyme takes different forms during development and differentiation to allow it to respond to different regulatory environments. A second explanation for the diversity of holoenzymes is that the purified holoenzymes represent subcomplexes of larger entities have been artifactually disrupted. It is likely that holoenzymes and probably all multisubunit complexes larger than a megadalton are particularly sensitive to the extreme conditions of ionic strength and hydrodynamic shear that are consequences of conventional protein purification procedures. It is reasonable to believe that there are multiple forms of RNA polymerase II holoenzyme in vivo. As described herein, the cloning and sequencing of a human SRB gene and the isolation and characterization of a mammalian RNA polymerase II holoenzyme complex has now been reported. Based on these results, it is reasonable to believe that the mammalian holoenzyme is associated with general transcription factors and additional SRB proteins as in the yeast holoenzyme. Using the techniques described herein, for elucidating the components of the yeast holoenzyme, these specific components associated with the mammalian holoenzyme can be identified. For example, antibodies against hSRB7 can be used to immunoaffinity purify the mammalian holoenzyme as described in Thompson, N.E., et al. , J Biol Chem. 265:7069-77 (1990) . Individual subunits of purified holoenzyme can then be isolated and microsequenced. Oligonucleotide primers for cloning can be designed by reverse translation of these sequences. The primers used for gene isolation of hSRB7 can be used in a two-hybrid system to isolate additional components of the holoenzyme as described in, e.g., Ausubel, F.M., et al. Current Protocols in Molecular Biology (Current Protocols, 1994); Fields, S. __ Song, 0., Nature ,340:245-6 (1989). hSRB7 can also be used as a probe to isolate additional proteins in the holoenzyme by screening an expression library with labeled hSRB7 protein (Ausubel, F.M., et al. Current Protocols in Molecular Biology (Current Protocols, 1994) . hSRB7 can also be used in an affinity column to purify additional proteins in the holoenzyme. (Thompson, CM. et al . , Cell, 73:1361-75 (1993); Ausubel, F.M., et al. Current Protocols in Molecular Biology (Current Protocols, 1994)). The hSRB7 gene sequence (SEQ ID NO: 36), or a fragment thereof, can be used as a probe to isolate additional SRB7 homologs. For example, a^ recombinant library from the appropriate organism can be screened with labeled hSRB7 DNA to identify homologous genes as described in, e.g., Ausubel, F.M., et al., Current Protocols in Molecular Biology, (Current Protocols, 1994) . Recombinant DNA libraries of chimeras between random DNA from an organism and the C-terminal coding region of ySRB7 can be screened for SRB7 homologs that complement a yeast SRB7 deletion mutation. Highly conserved SRB7 amino acid sequences have been identified which will allow cloning of SRB7 sequences from other organisms. These amino acid sequences are MXDRLTLQ (SEQ ID NO: 38) and LIDSLP (SEQ ID NO: 39) . Degenerate oligonucleotides based on the reverse translation of these amino acid sequences can be used to isolate other SRB7 homologs. In addition, antibodies raised against these peptides, or against hSRB7, or fragments thereof, can be used to screen expression libraries for homologs, again as described in, e.g., Ausubel, F.M., et al. , Current Protocols in Molecular Biology, (Current Protocols, 1994) . RNA Polymerase II Holoenzyme Contains SWI/SNF Regulatory Proteins Regulation of class II genes involves a complex interplay among gene-specific activators and cofactors, the general transcription apparatus, and chromatin. Gene specific activities bind to promote and stimulate transcription, at least in part, by binding and recruiting the general transcription apparatus. Chromatin structure can affect the transcriptional activity of genes by blocking access of the transcription apparatus to promoters. The SWI and SNF regulatory proteins are global regulators that function by antagonizing repression mediated by nucleosomes, altering chromatin structure to facilitate binding of the transcription apparatus. The yeast SWI genes were first identified as positive regulators of HO transcription and SWI1, SWI2, and SWI3 were later shown to be required for the activation of a broad spectrum of inducible genes in vivo . Similarly, the SNF genes were originally identified as positive regulators of SUC2 and SNF2, SNF5, and SNF6 were subsequently found to be essential for activation of a diverse set of inducible genes. Further study revealed that SWI2 and SNF2 are the same gene, referred to herein as SWI2/SNF2. Genetic evidence indicated that the SWI and SNF genes are involved in similar processes in gene activation. More specifically, genetic and biochemical evidence implicated the SWI/SNF proteins in chromatin remodeling via nucleosome disruption. As described herein, the yeast RNA polymerase II holoenzyme contains SWI2/SNF2, SWI3, SNF5 and SNF11. The SWI/SNF proteins are components of the SRB complex, also known as the mediator, which is tightly associated with the RNA polymerase II CTD. Both the holoenzyme and the SRB/SWI/SNF complex, as well as the SWI/SNF proteins have ATP-dependent nucleosome disruption activities previously ascribed to the SWI/SNF complex. In addition, the holoenzyme facilitates the binding of TBP to nucleosomal DNA in an ATP-enhanced manner. The data described herein strongly suggests that recruitment of the holoenzyme to a specific promoter in vivo provides a means to facilitate TBP binding, regardless of the nucleosome structure at that promoter. The holoenzyme can enhance binding of TBP and TFIIA to a mononucleosome in vitro in the absence of ATP, a result compatible with evidence that the polymerase and general transcription factor components of the holoenzyme provide additional protein-protein and protein-DNA interactions that should stabilize TBP binding. Holoenzyme-facilitated TBP binding to a mononucleosome is greater in the presence of ATP, which presumably reflects the ATP dependent nucleosome disruption activity of the SWI/SNF proteins. The SRB/SWI/SNF complex is tightly associated with the RNA polymerase II CTD. Independent attempts to purify various SRB proteins by column chromatography have resulted in purification of the same multiprotein complex: the RNA polymerase II holoenzyme. Only very small amounts of SRB protein can be detected that are not associated with the holoenzyme. Two different methods have been described which permit partial purification of an SRB subcomplex. An SRB complex can be isolated using a CTD affinity column, or by releasing it from a holoenzyme preparation by using monoclonal anti-CTD antibodies. As described herein, preparations of the SRB complex obtained by CTD-affinity chromatography were further purified. The SRB and SWI/SNF proteins coelute in the final step of the purification. Also described herein, the SRB complex isolated by anti-CTD antibody release contains SWI and SNF proteins. More specifically, the RNA polymerase II holoenzyme, and its SRB/SWI/SNF subcomplex, contains SWI2/SNF2, SWI3, SNF5, and SNF11. Additional genetic and biochemical data indicate that it is highly likely that SWI1 and SNF6 are also subunits of this complex, along with additional components. Since SWI2/SNF2 and SNF5 are stoichiometric components of the holoenzyme, and yeast cells contain 2000 - 4000 molecules of RNA polymerase II holoenzyme, there are at least 2000 molecules of SWI2/SNF2 and SNF5 molecules per cell. It has been estimated that there are between 50 and 150 copies of a SWI/SNF complex in yeast cells (Cote, J. et al . , Science. 256:53-60 (1994)). One interpretation of these results is that most SWI/SNF protein resides in the RNA polymerase II holoenzyme, and the form of SWI/SNF complex purified is the small amount of SWI/SNF protein that is in the process of assembly into holoenzyme or, alternatively, it represents a subcomplex that can be-dissociated from the holoenzyme. The ability to immunoprecipitate very similar holoenzyme complexes from crude yeast fractions using anti-SRB and anti-SWI antibodies suggests that most of the SWI/SNF proteins in these fractions are associated with the holoenzyme. If the SRB and SWI/SNF proteins were in separate complexes, then the relative ratios of SRB and SWI/SNF proteins would differ in the anti-SRB and anti-SWI immunoprecipitates. However, the similar relative ratios of SRB and SWI/SNF proteins found in immunoprecipitates obtained with anti-SRB and anti-SWI antibodies indicates that the SRB and SWI/SNF proteins are components of the same complex in the crude extract. SWI/SNF proteins and their functions appear to be highly conserved in eukaryotes. Putative homologues of SNF2/SWI2 include Drosophila brahπia, human hbr and hBRGl , and a mammalian homologue of SNF5, called INI1. Recently, a human SWI/SNF complex has been partially purified which has nucleosome disruption activities similar to those of the yeast SWI/SNF complex (Kwon, H. et al . , Nature. 370:477-481 (1994)). The human SWI/SNF complex contains both hBRGl and INI1 proteins. Like the yeast SWI/SNF complex, the human SWI/SNF complex facilitates the binding of activators to nucleosomal DNA. The presence of the SRB/SWI/SNF complex in the RNA polymerase II holoenzyme has implications for the mechanisms involved in transcription activation in vivo. Dynamic competition between chromatin proteins and an activator for a specific DNA site could be resolved in favor of the activator once the SWI/SNF-containing holoenzyme was recruited to the promoter. In this model, the activator and the holoenzyme both contribute to stable transcription initiation complex formation; the activator recruits the holoenzyme by binding to a subset of its components and the SWI/SNF components of the holoenzyme enhance the stability of the activator-DNA interaction by destabilizing nucleosomes. Methods Of Modifying Gene Transcription As described herein, Applicants have identified genes encoding yeast and human SRB proteins which act as positive and negative regulators of gene transcription via interaction with RNA polymerase II. In particular, Applicants have demonstrated that SRB2 and SRB5 positively regulate CTD function and that SRB8 and SRB9 negatively regulate CTD function. In addition, Applicants have shown that the SRB proteins are an integral part of a multisubunit holoenzyme complex comprising SRB proteins, SWI/SNF proteins, and RNA polymerase II, and is associated with general transcription factors and other components necessary for transcription activation. This RNA polymerase II holoenzyme is preassembled and readily recruited to a DNA promoter, and, when supplemented with factor a (TFIIE) and TATA-binding protein, is capable of site- specific gene transcription. Importantly, the RNA polymerase II holoenzyme described herein is responsive to transcriptional activators, such as GAL4-VP16, unlike purified RNA polymerase II combined with previously known transcription factors. Thus, the regulatory proteins contained in the RNA polymerase II holoenzyme act as signal processors which confer responsiveness to both positive and negative activators, most likely through interaction with RNA polymerase II. Because of the critical role the SRB and SWI/SNF proteins play in the regulation of gene transcription, it is apparent that modification, or alteration, of one, or more, of the SRB or SWI/SNF proteins results in the modification, or alteration, of the RNA polymerase II holoenzyme and thus, modify, or alter, gene transcription. Based on this model of an RNA polymerase II holoenzyme, it is reasonable to propose methods of modifying gene transcription in a cell by modifying the initiation of transcription by the RNA polymerase II holoenzyme. Modification of the RNA polymerase II holoenzyme can be accomplished in a number of ways. One, or more, SRB or SWI/SNF proteins can be prevented from associating with other SRB or SWI/SNF proteins, thus, preventing the formation of the holoenzyme complex. One, or more, SRB or SWI/SNF proteins can be modified such that, even though the holoenzyme complex is formed, the holoenzyme is not functional, e.g., it no longer has the ability to initiate gene transcription) . Modification of the RNA polymerase holoenzyme can also be accomplished by modifying the SRB or SWI/SNF regulatory proteins such that the signals sent to the RNA polymerase II holoenzyme are altered, leading to either a stimulation or suppression of transcription. This can be accomplished by the use of a substance that specifically interacts with a component of the RNA polymerase II holoenzyme. Substances used in the methods described herein can be proteinaceous in nature, such as peptides (comprised of natural and non- natural amino acids) and peptide analogs (comprised of peptide and non-peptide components) , or can be non- proteinaceous in nature, such as small organic molecules. The substance can also be a genetically engineered SRB or SWI/SNF protein with an altered amino acid sequence. These substances would be designed to bind to, or interact with the SRB or SWI/SNF protein based on the DNA or amino acid sequences of the SRB or SWI/SNF proteins described herein, or the antibodies reactive with the SRB or SWI/SNF proteins described herein. For example, a substance can be identified, or designed, that specifically interferes with the interaction of one, or more SRB or SWI/SNF proteins in the holoenzyme complex. These substances would mimic a site on at least one SRB or SWI/SNF protein (e.g., a binding site on the SRB or SWI/SNF protein) that interacts with another SRB or SWI/SNF protein, thus preventing, or inhibiting, the association of at least one SRB or SWI/SNF protein as part of the holoenzyme complex. Thus, formation of the RNA polymerase II holoenzyme is prevented. By preventing the holoenzyme from forming, transcription would be inhibited. Alternatively, these substances would mimic a site on the RNA polymerase II which interacts with, or binds to, at least one SRB or SWI/SNF protein, again preventing, or inhibiting an SRB or SWI/SNF protein from interacting with the RNA polymerase II CTD. Thus, the RNA polymerase II holoenzyme complex would be formed, but it would not be a functional holoenzyme complex, capable of initiating transcription. Monoclonal or polyclonal antibodies (e.g, the polyclonal antibodies described herein) specific for one, or more, of the SRB or SWI/SNF proteins can also be used to prevent, or inhibit, the SRB or SWI/SNF proteins from participating in the initiation of gene transcription. The antibody would react with, or bind to, the SRB or SWI/SNF protein and, for example, prevent the SRB or SWI/SNF protein from associating with other SRB or SWI/SNF proteins and forming the holoenzyme complex. Thus, gene transcription is inhibited. The RNA polymerase II holoenzyme is unusual in that it can respond to transcriptional activators, whereas RNA polymerase II or transcriptional factors alone cannot. Thus, the SRB proteins act as sort of a "regulatory glue" to hold the transcriptional complex together and confer responsiveness to the activator on the holoenzyme. Because of the presence of the SRB proteins, gene transcription can be up-regulated or down-regulated. Thus, substances, including antibodies, that bind to one or more SRB proteins in the holoenzyme complex, would result in up-regulation or down-regulation of gene transcription. For example, SRB2 and SRB5 have been shown to positively regulate gene transcription. Thus, a substance which interacts with either the SRB2 or SRB5 proteins, or both proteins, can decrease, or reduce, the activation of gene transcription. In contrast, substance that interacts with SRB8 or SRB9, which have been shown to . negatively regulate gene transcription, can stimulate gene transcription. Alternatively, a mutant SRB protein can be introduced into the cell which is incapable of processing regulatory signals, thus preventing gene transcription. Certain of the SRB proteins also contain amino acid sequences characteristic of protein kinase domains, thus, indicating that they have kinase activity. It is reasonable to predict that these SRB proteins play a role in the phosphorylation of SRB proteins, or other proteins or factors involved with the transcription machinery. Thus, modifying, or altering the kinase activity of one, or more, SRB proteins can also modify, or alter, gene transcription by e.g., preventing the phosphorylation of another transcription factor. Both the RNA polymerase II holoenzyme of the present invention and the SRB/SWI/SNF complex have ATP- dependent nucleosome disruption activities. In addition, the holoenzyme facilitates the binding to TBP to nucleosomal DNA in an ATP-enhanced manner. As described herein, data indicate that the SRB/SWI/SNF complex contributes chromatin remodeling activity to the RNA polymerase II holoenzyme. Thus, gene transcription can be up-regulated or down-regulated via the SWI/SNF proteins. For example, substances, including antibodies, that bind to one, or more SWI/SNF proteins in the holoenzyme complex, would result in up- regulating or down-regulating of gene transcription. Alternatively, a mutant SWI/SNF protein can be introduced into the cell. The mutant protein is incapable of participating in the formation of, or functional activity of the SWI/SNF protein complex, thus, preventing the formation of a functional SWI/SNF complex, thus preventing gene transcription. Transcription of DNA sequences, or translation of mRNA sequences, encoding the SRB or SWI/SNF proteins can also be inhibited or decreased, resulting in decreased production of, or complete absence of one, or more critical SRB or SWI/SNF proteins. Gene transcription can be modified by introducing an effective amount of a substance into a cell that inhibits transcription of one or more of the SRB or SWI/SNF genes, or that inhibits translation of mRNA encoding one or more of the SRB or SWI/SNF gene products. For example, antisense nucleotide sequences can be introduced into the cell that will hybridize with the gene encoding one of the SRB proteins and inhibit transcription of the gene. Alternatively, an antisense sequence can be introduced into the cell that will interfere with translation of the mRNA encoding a SRB or SWI/SNF protein. The substances described in the present invention can be identified and tested for their ability to modify gene transcription using an in vi tro transcription assay. For example, DNA of interest (i.e., DNA to be transcribed) can be admixed with purified RNA polymerase II, the SRB and/or SWI/SNF proteins, transcription factors b, e, g or a (or homologies thereof) , TBP and the substance to be tested and maintained under conditions sufficient for DNA transcription to occur. The resulting combination is referred to as a test mixture. DNA transcription can be assessed by determining the quantity of mRNA produced. DNA transcription is determined in the presence of the substance being tested and compared to DNA transcription in the absence of the test substance taking place under identical conditions (e.g., a control mixture) . If DNA transcription occurs to a lesser extent in the test mixture (i.e., in the presence of the substance being evaluated) than in the control mixture, the substance has interacted with one, or more SRB proteins in such a manner as to inhibit DNA transcription. If DNA transcription occurs to a greater extent in the test mixture than in the control mixture, the substance has interacted with one, or more, SRB or SWI/SNF proteins in such a manner as to stimulate DNA transcription. The SRB or SWI/SNF proteins can also be genetically altered, such as by site directed mutagenesis, resulting in a SRB or SWI/SNF protein with altered activity. Genetically altered SRB or SWI/SNF proteins would affect gene transcription. For example, one, or more genetically altered SRB or SWI/SNF proteins may be introduced into a cell via a liposome, or linked to a carrier protein known to cross the cell membrane. Alternatively, DNA encoding such a protein may be introduced into the cell using for example, a vector containing the DNA sequence via standard laboratory procedures. These genetically altered SRB proteins would be impaired in their ability to interact with naturally occurring (i.e., unmodified) SRB or SWI/SNF proteins, thus inhibiting, the formation of the RNA polymerase II holoenzyme, or inhibiting the formation of a functional holoenzyme, thus inhibiting gene transcription. In addition, DNA encoding a wild- type SRB or SWI/SNF proteins with biological activity (i.e., being capable of participating in gene transcription) may be introduced into the cell to supplement a diminished supply of endogenous SRB or SWI/SNF protein. The wild-type SRB or SWI/SNF protein would be expressed in the cell, thus increasing the level of SRB or SWI/SNF protein in the cell, resulting in an increased amount of RNA polymerase II holoenzyme being formed, and, thus, increasing gene transcription. The ability to modify gene transcription is useful in three categories of human disease: 1) inherited, or genetic, disease; 2) acquired disease, not of infectious origin; and 3) acquired disease, of infectious origin. Changes in gene transcription in these three situations will contribute to changes in the manifestation of the disease. For example, in an inherited disease, the level of expression of a critical gene is altered relative to the expression of the gene in an individual who does not manifest the disease. If the amount of gene product produced is inadequate, the introduction of a substance into a cell which interacts with at least one SRB protein, resulting, for example, in stimulating gene transcription will result in increased gene product, thus, improving the condition of the individual. In the example of an acquired disease that is not of infectious origin, such as cancer, modifying gene transcription will also modify the disease state. Typically a cancer is the result of the loss of growth control concomitant with increased transcriptional activity, in a particular cell type. In this case, a substance that interacts with one, or more SRB proteins, thus decreasing gene transcription, will improve the condition of the individual. Because cancer cells have an extraordinarily high rate of gene transcription, the substances will significantly affect the rate of gene transcription in cancer cells, (i.e., rapidly growing cells) but insignificantly affect the rate of gene transcription in normal cells (analogous to the use of anti-metabolites in the treatment of cancer) . In the case of acquired disease where the disease is the result of an infectious agent, such as a bacteria or a virus, an increase in the transcription of genes encoding proteins involved in the immune response would result in the improvement of the condition of the individual. For example, in HIV infection, a substance which interacts with SRB8 or SRB9, which negatively regulate gene transcription, could be targeted for delivery to lymphocytic cells, resulting in the increase of transcription of important lymphocytic proteins. Also, in the case of some virus infections, such as vaccinia virus, host cell gene transcription is completely shut down by the virus. A substance as described above, targeted to the virally infected cells, would turn on the host cell's transcription machinery. Alternatively, for some viruses, i.e., adenovirus, it may be advantageous to turn down the host cell's transcription machinery (as described above for cancer) . As described herein, the RNA polymerase II holoenzyme plays a critical role in gene transcription in eukaryotes. Homologs of the SRB and SWI/SNF proteins can exhibit differences in sequence identity and these differences can be exploited in designing substances (e.g., drugs) that target eukaryotic pathogens without the interfering with the hosts' gene transcription machinery. For example, a drug can be identified, or designed, e.g., an antisense DNA seguence that hybridizes to a fungal SRB DNA sequence and thus this inhibits gene transcription in the fungus. The antisense nucleotide will specifically hybridize to fungal SRB DNA, but will not hybridize with human SRB DNA, thus, gene transcription in the human host is not compromised. Eukaryotic pathogens can include, e.g., fungi such as Candida or Pneumocystis; parasites such as Plasmodium and Schistosoma; pathogenic worms; and insects that affect animals or agricultural crops. It is important to note that only the modification, or alteration, of gene transcription is necessary to see an effect. The inhibition or stimulation of gene transcription may be partial inhibition or partial stimulation. Complete inhibition, or complete stimulation of gene transcription is not necessary. All that is needed is to diminish or enhance gene transcription relative to the rate of gene transcription in a cell that does not have the substance introduced in to it. Thus, as defined herein, an effective amount of a substance to modify gene transcription is that amount of the substance necessary to diminish or enhance gene transcription relative to the rate of gene transcription in a cell that does not have the substance introduced into it. Introduction of a substance into the cell may be by any conventional means, such as the use of a carrier protein which will interact with the cell membrane; attachment to an antibody which reacts with a cell surface antigen; or encapsulation in a liposome. If the substance is proteinaceous in nature, e.g., a peptide, DNA encoding the substance can be introduced into the cell, and the substance can be genetically expressed in the cell. Alternatively, the DNA can be directly introduced into a cell, e.g., an epidermal cell, via a "gene gun", or other electroporation technique. Other methods of cell targeting known to those of skill in the art may also be used. According to this invention, the substances can be formulated into pharmaceutical compositions containing a pharmaceutically acceptable carrier and/or other excipients using conventional materials and means. They can be administered using conventional routes such as parenteral, oral, inhalation and the like, using appropriate formulations. Other methods of passive or active transport of small molecules known to those of skill in the art can also be employed. Suitable pharmaceutically acceptable carriers in¬ clude, but are not limited to, water, salt solutions, alcohols, gum arabic, vegetable oils, benzyl alcohols, polyethylene glycols, gelatine, carbohydrates such as lactose, amylose or starch, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid esters, hydroxymethycellulose, polyvinyl pyrrolidone, etc. For parenteral application, particularly suitable are injectable, sterile solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants, including suppositories. It will be appreciated that the actual preferred effective amounts of substance in a specific case will vary according to the specific substance being utilized, the particular compositions formulated, the mode of application, the particular situs of application, and the organism being treated. If administered to an individual, dosages for a given recipient will be determined on the basis of individual characteristics, such as body size, weight, age and the type and severity of the condition being treated. Also encompassed by the present invention are methods of diagnosing disease conditions in humans resulting from abnormalities in the production of, or in the SRB, or SWI/SNF proteins themselves. These methods are based on the detection, and/or quantification, of e.g., SRB proteins, DNA or RNA in the cell, or in a biological sample. A biological sample includes biological fluids such as blood, urine, feces, tissue samples or cells isolated from these sources. For example, a method of detecting SRB DNA in a biological sample can be accomplished by obtaining a sample and isolating the DNA by known laboratory procedures resulting in DNA available for hybridization with a DNA probe. The DNA probe would be a nucleic acid probe having a nucleic acid sequence of sufficient complementarity to a SRB DNA sequence such that it is capable of selectively hybridizing with SRB DNA under standard hybridization conditions. These conditions may be conditions of high stringency as determined by one of skill in the art. Detection and quantification of SRB DNA can be determined using standard techniques of detection, such as fluorescence detection, if fluorescent-tagged probes are used. An immunoassay can also be used to detect, or quantify, the amount of SRB, or SWI/SNF protein present in a cell. Alternatively, an immunoassay can also be used to determine the biological activity of a SRB or SWI/SNF protein. For example, a biological sample can be obtained and reacted with an antibody under conditions suitable for binding of the antibody to a SRB protein. If the sample contains SRB protein, the antibody will bind to the protein, forming an antibody/SRB protein complex. This antibody/SRB complex can be detected using, for example, a second antibody which is detectably-tagged and which would bind to this complex as is known to those of skill in the art. The present invention is illustrated by the following examples, which are not intended to be limited in any way. EXAMPLES Example 1: The SRB2 Gene and Encoded Protein Molecular Analysis of SRB2 pCT21 contains the SRB2 gene within a 6.2 kb Sacl- BamHI DNA fragment from pCT19 (Nonet, M.L, and Young, R.A., Genetics 123: 715-724 (1989), inserted into the Sacl-BamHI sites of the pUC18 poly-linker. A set of nested deletions of pCT21 was created as described previously (Nonet, M.L., et al . , Mol. Cell Biol. 2:1602-1611 (1987) , and SRB2 and surrounding DNA sequenced from double-stranded plasmid DNAs. pCT20 is a pUC18 plasmid that contains the 6.2 kb Sacl-BamHI DNA fragment from pCTl inserted into the Sacl-BamHI sites of the poly-linker. The SRB2-1 mutation was deduced by sequencing double-stranded pCT20 DNA using a set of six 20 bp oligonucleotide primers: CT100 = ACTACAATCCGGGCTTATCC (SEQ ID NO: 19) CT101 = TCTTGGTCTCAAACTCGCCC (SEQ ID NO: 20) CT102 = GTTGTCCTTGATTAGCACGG (SEQ ID NO: 21) CT200 = CCAAAGTGAAATTTTACTGG (SEQ ID NO: 22) CT201 = TAGACTTTCGGACGTACCGG (SEQ ID NO: 23) CT202 = CGGTGAGACGTTGATCTTGG (SEQ ID NO: 24) Total RNA was isolated from wild-type and from rna2 yeast cells, and poly(A) + RNA was purified from these preparations, utilizing procedures described in Elder et al . , Proc. Natl. Acad. Sci. USA 80:2432-2436 (1993) . Northern analysis were performed as described in Nonet, M. et al. , Cell. 50:909-15 (1987). The 550 bp Ncol DNA fragment from pCT21 was nick-translated and used as a probe. In addition, strand-specific probes were generated and used to identify the orientation of the SRB2 transcript. Oligonucleotides were synthesized complementary to sequences 932-952 and 1206-1226 and used for primer extension analysis with poly(A) + RNA to locate the 5' end of the SRB2 transcript. DNA Constructs All DNA manipulations were performed according to Sambrook et al . , Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory 1989) . Site-directed mutagenesis was performed as described in Kunkel, T.A., et al., Meth. Enzvmol. 154:367-382 (1987). The entire coding region of SRB2 was deleted from pCT29 using the primer GAAGGAAGGGGCAGGTGGTTACGCGGTGTATACGTATAG (SEQ ID NO: 25) . This replaced the coding sequence of SRB2 with an Hpal site, creating pCM28-2. To introduce HIS3 into the Hpal site, the 1.75 kb BamHI DNA fragment from pRB328 was blunt-ended by treatment with Klenow and ligated into pCM28-2 to produce pTK33 (containing the deletion allele srb2Δl: :HIS3) . The 12CA5 epitope coding sequence (Kolodziej, P.A., et al . , Mol. Cell. Biol. 10:1915-1929 (1990)) was introduced contiguous to the carboxyl terminus of the SRB2 protein coding sequence of pCT29 using the primer AGCATTCGTAAGAACTCAAGCGTAGTCTGGGACGTCGTATGGGTACAGCTCCAGA GCACGAAC (SEQ ID NO: 26), producing pTK2. The epitope- tagged SRB2 is fully able to complement the deletion allele srb2Δl. The intron of SRB2 was removed from the gene on pTK2, using the oligomer TCCACGAATATAACAGCTGATTTTCCCATG (SEQ ID NO: 27), to generate pTK21. Two primers, TCGGCATATGGGAAAATCAGCTGTTAT (SEQ ID NO: 28) and CCGTGGATCCTCACAGCTCCAGAGCACGAA (SEQ ID NO: 29), were used to PCR amplify the coding region of the epitope- tagged SRB2 gene of pTK21 for insertion into the Ndel- BamHI sites of the bacterial expression vector pET3a (Studier, F.W. and Moffatt, B.A., J. Mol. Biol. 189:113-130, (1986)), forming pTK27. To construct isogeneic strains for analyzing the growth phenotypes of strains containing various SRB2 alleles, pTK44 and pTK45 were constructed by inserting the 2.5 kb Xbal-Sall fragment from pCT25 (SRB2-1) or pCT27 (SRB2) into YCp405, pCT25 is identical to pCT27 except that it contains the SRB2-1 mutation. Several plasmid DNAs were used as templates for in vitro transcription. pSL187, a gift of Sha-Mei Liao (Whitehead Institute) , is identical to pGAL4CG- (Chasman, D.I., et al . , Nature 339:679-684 (1989)) except that the GAL4 binding site has been removed. pJJ460 was a kind gift of Michael Woontner and Judith Jaehning (Wootner, M., et al . Mol. Cell. Biol. 11:4555- 4560 (1991)). Genetic Analysis Analysis of the growth phenotypes of cells containing CTD truncation mutations in SRB2 wild-type cells has described previously (Nonet, M. et al . , (1987) ; Nonet and Young, (1989) ) , and the experiments described here were performed similarly. To create strains for analysis of CTD length requirements in an srb2Δl back-ground, strain Z426 was transformed with the 3.3 kb EcoRI fragment containing srb2Δl::HIS3 from pTK33. Z426 has a genomic deletion of RPBl covered by a wild-type copy of RPBl on a URA3 CEN plasmid (Table 2) . A His + colony confirmed to have SRB2 replaced by srb2Δl::His by Southern analysis was designated Z404. The viability of cells containing CTD truncations in combination with the srb2Δl allele was assayed by plasmid shuffle with strain Z404 (Boeke, J., et al . Meth. Enzvmol. 154:164-175 (1987)). Plasmids containing the various CTD truncations have been described (Nonet et al., (1987)). Surviving strains were tested for temperature sensitivity at 38°C, cold sensitivity at 12°C, and inositol auxotrophy was previously described (Nonet and Young, (1989)). Strains were previously constructed for analysis of CTD length requirements in an SRB2-1 background (Nonet and Young, (1989)). Table 2. Strain List Common Strain Name Genotype Z494 YTK54 Mat x ura-352 his3Δ200 leu2-77 ade2-101 lys2-801 trpl-901 tyrl-501 gal4-542 gal80-538 rpblΔl82 srb2Δl::HIS3 [pRP112 Z405 RY1 (URA3 RPBl)] Z406 YTK35 Mat or rna2-l ural adel his 7 lys2 tyrl gal Mat ura3-52 his3Δ200 leu2-77 ade2-101 lys2-801 trpl901 tyrl- 501 gal4-542 gal80-538 rpblΔl82 srb2Δl::HIS3 [pC6 (rpbl-104 Z407 YTK34 LEU2) pTK44 (SRB2 LYS2)] Mat a ura3-52 his3Δ200 leu2-77 ade2-101 lys2-801 trpl901 tyrl- 501 gal4-542 gal80-538 rpblΔl82 srb2Δl::HIS3 [pC6 (rpbl-104 Z408 YTK36 LEU2) pTK45 (SRB2 LYS2) ] Mat a ura3-52 his3Δ200 leu2-77 ade2-101 lys2-801 trpl901 tyrl- 501 gal4-542 gal80-538 rpblΔl82 srb2Δl::HIS3 [pRP114 (RPBl Z409 YTK38 LEU2) YCP405(LYS2)] Mat ura3-52 his3Δ200 leu2-77 ade2-101 lys2-801 trpl901 tyrl- 501 gal4-542 gal80-538 rpblΔl82 srb2Δl::HIS3 [pRP114 (RPBl Z410 YTK37 LEU2) pTK44(SRB2-l LYS2)1 Mat or ura3-52 his3Δ200 leu2-77 ade2-101 lys2-801 trpl901 tyrl- 501 gal4-542 gal80-538 rpblΔl82 srb2Δl::HIS3 [pRP114 (RPBl Z411 YTK13 LEU2) [pRP114(RPBl LEU2) pTK45 (SRB2 LYS2) ] Z412 YTK14 YTK54 [pV17 (LEU2 rpbl-115)] Z413 YTK15 YTK54 [pV8 (LEU2 rpbl-112)] Z414 YTK16 YTK54 [pV4 (LEU2 rpbl-109)] Z415 YTK17 YTK54 [pC23 (LEU2 rpbl-105)] Z416 YTK18 YTK54 [pC3 (LEU2 rpbl-103)] Z417 YTK19 YTK54 [pV5 (LEU2 rpbl-110)] Z418 YTK20 YTK54 [pV3 (LEU2 rpbl-108)] Z419 YTK21 YTK54 [pV7 (LEU2 rpbl-111) ] Z420 YTK22 YTK54 [pV19 (LEU2 rpbl-117)] Z421 YTK23 YTK54 [pCl (LEU2 rpbl-101) ] Z422 YTK24 YTK54 tpC2 (LEU2 rpbl-102)] Z423 YTK25 YTK54 [pC6 (LEU2 rpbl-104)] Z424 YTK72 YTK54 [pV20 (LEU2 rpbl-118)] Z425 YTK73 Mat his3Δ200 leu2-3 leu2-112 ura3-52 trplΔl ade2-101 Z426 N402 Mat a his3Δ200 leu2-3 leu2-112 yra3-52 trplΔl lys2-801 srb2Δl: :HIS3 Z427 CM94 Mat a ura3-52 his3Δ200 leu2-77 ade2-101 lys 2-801 trpl-901 tyrl-501 gal4-542 gal80-583 rpblΔl82 [pRP112 (URA3 RPBl)] Mat a/Mat his3Δ200/his3Δ200 leu 2-3 leu2-112/leu2-112 ura3- 52/ura3-52 trplΔl/trplΔl ADE2/ade2 LYS2/lys ' 2-801 Strains containing combinations of SRB2 alleles and CTD truncation alleles were assayed for growth at 38°C, 5 25°C, and 12°C and for their ability to grow on minimal medium lacking inositol . 0 Example 2 : The SRB4 , SRB5 , SRB6 Genes and Encoded Proteins Yeast strains and plasmids are listed in Tables 3 and 4, respectively. Yeast medium was prepared as described (Nonet, M. L. and Young, R. A., Genetics 123:715-724 (1989)), except pyruvate medium, which consists of synthetic complete (SC) medium with 2% pyruvic acid (Sigma) as a carbon source. Yeast transformations were done using a lithium acetate procedure (Schiestl, R.H. and Gietz, R.D., Curr. Genet. 16:339-346 (1989)). Plasmid shuffle techniques were performed as described by Boeke, J., et al. Meth. Enzymol. 154:164-175 (1987)), using 5-fluoroorotic acid (5-FOA) as a selective agent against URA3 plasmids. ■ 66- •67- -68- Table 4. Plasmids Plasmid Description PCT37 srb5Δl::_RA3hisG, created by ligation of SRB5-1 EcoRI-BamHI from PCT20 with EcoRI-BamHI of pSP72 ( Promega ) , followed by PCR with the oligonucleotides TAATCATTGGCACCTGGGCA and CTTTTCTTCTTAATATGGAA and ligation of PCR product with Bgllll ( blunt ) -BamHI (blunt) U A3 kan hisG cassette from B2178 (G.R. Fink ) . PCT39 pcT32 containing SRB5, obtained by gap repair of vector containing fragment of nCT32 Sacl-Xhol digest. PCT98 pET-3a (Studier and offat, 1986) with SRB5. Ndel site at ATG of SRB5 created by ligation of SRBS EcoRI-BamHI from pCT39 with EcoRI- BamHI of pBSIIS (-) (Stratagene) , followed by site-directed mutagenesis. Ndel-EcoRI (blunt ) SRB5-containing fragment was then liσated with Ndel-BamHI (blunt) -digested pET-3a. SRBS pCT3 with 3 kb genomic (Z554) Sau3A fragment containing SRBS-i inserted at Xhol site. pCT3 with 1.0 kb subgenomic (pCT2S ) Sau3A fragment containing SRB6- 1 inserted at Xhol site. srb6Δl::ϋRA3hisG, created by ligation of SRBS-1 EcoRI-BamHI from pCT29 with EcoRI-BamHI of pSP72 (Promega ) , followed by PRC with oligonucleotides TAAAAAGGCGGTATTTATCT and CATATAGTGCCTGGTTGCTC and ligation of PRC product with Bgllll ( blunt ) -BamHI (blunt) URA3 kan hisG cassette from B2178 (G.R. Fink ) . pCT29 with SRB6, obtained by gap repair of vector containing fragment of oCT 9 Ball-Sphl digest. EU2 CEN pUNlOS (Elledge and Davis, 1988 ) with SRBS, created by ligation of SRBS BamHI (blunt) -Sail ( blunt ) from pCT40 with Smal- digested pUNlOS. pCTliε PGEX-2T (Smith and Johnson, 1988 ) with GST-SRBS fusion. Ndel site at ATG of SRB6 created by ligation of SRBS Sall-Xbal from pCT40 with Sall-Xbal of pBSIISK(+) (Stratagene), followed by site- directed mutagenesis. Ndel (blunt) -Xbal SRB6-containing fragment was then liσated with BamHI (blunt)-digested PGEX-2T. Extragenic suppressors of the cold-sensitive phenotype of Z551 were isolated as previously described ( Nonet, M. and Young, R.A. , Genetics 123:715-724 ( 1989)) . Dominant suppressors were identified by mating to Z26, selecting against the presence of pRPH2 using 5-FOA and assaying growth at 12°C on YEPD. Diploids able to grow at 12°C contained a dominant suppressor. Isogeneic wild-type, SRB4-1, SRB5 1, and SRB6-1 strains containing various RPBl alleles (rpbl-4, 10 rpbl-5, rpbl-6, rpbl-10, rpbl-12, rpbl-13, rpbl-14, rpbl-15, and rpbl-18) on LEU2 CEN plasmids were constructed using Z26, Z555, Z556, and ZΞΞ7 and plasmid shuffle techniques. Isogeneic wildtype, SRB4-1, SRB5- 1, and SRB6-1 strains containing rpbl-1 on a URA3 CEN plasmid, pRPl-1 [U] were constructed by transforming Z551, Z552, Z553, and Z554 with pRPl-l[U] , followed by growth in SC-Ura medium to permit loss of pC6. Growth assays were performed by suspending similar numbers of cells in water and transferring equal volumes to agar plates with a 48 prong apparatus. Deletions of SRB4, SRB5, and SRB6 were created by a single step disruption method (Rothstein, R. , Meth. Enzvmol. 194:281-301 (1991)) . Z558 was transformed with the desired DNA fragment and plated on the proper selective medium. Southern analysis was used 10 confirm that a single copy of the desired SRB gene had been deleted. The diploid was sporulated and tetrads (more than 20) were dissected on YEPD plates and scored for nutritional auxotrophies and growth at a variety of temperatures. Z565 was created by transformation with the EcoRI-Xbal fragment of pCT54 containing the srb4Δ2::HIS3 fragment and plating on SC-His medium. Two spores or fewer from each tetrad were viable, and these were all histidine auxotrophs, indicating that SRB4 is essential. To confirm that SRB4 is essential, Z565 was transformed with pCT15 (URA3 SRB4) , tetrads were dissected, and His + Ura + segregants were streaked to 5-FOA plates. They were unable to grow on 5-FOA-containing medium, confirming that SRB4 is essential. Z559 was created by transformation with the EcoRI-Sphl fragment of pCT37 containing the srb5Δl: :URA3-hisG fragment and plating on SC-Ura medium. Segregants scored 2:2 for uracil prototropy and air uracil prototrophs exhibited cold-sensitive, temperature-sensitive, and slow growth phenotypes, indicating that SRB5 deletion strains are conditionally viable. Z564 was created by transformation with the Bglll-BamHI fragment of pCT38 containing the srb6Δl: :URA3-hisG fragment and plating on SC-Ura medium. Two spores of fewer from each tetrad were viable, and these spores were all uracil auxotrophs, indicating that SRB6 is essential. To confirm that SRB6 is essential, Z564 was transformed with pCT66 (LEU2 SRB6) tetrads were dissected and Z566 was created by placing a Ura + Leu + segregant onto 5-FOA to select for the excision of the URA3 gene. Z566 was transformed with pCT40 (URA3 SRB6) , grown in SC-Ura medium to permit loss of pCT66, and then tested for growth on 5-FOA plates. No growth was observed on 5-FOA. Confirming that SRB6 is essential. Several strains were constructed for producing yeast nuclear extracts for in vi tro transcription assays. Z425 was mated to Z560, and tetrads were dissected to produce the wild-type Z561, srb5Δl: :URA3-- hisG strain Z562, and srb2Δl: :HIS3, srb5Δl:URA3-hisG strain Z563, Z562 and Z563 displayed identical temperature-sensitive, cold-sensitive and slow growth phenotypes. DNA Methods DNA manipulations were performed according to Sambrook et al., Molecular Cloning; A Laboratory Manual (Cold Spring Harbor Laboratory 1989) . Site directed mutagenesis was performed as described in Kunkel, T.A., et al . . Meth. Enzvmol. 154:367-382 (1987). Polymerase chain reaction (PCR) amplifications to produce pCT54 (srb4Δ2) , pCT37 (srbδΔl) and pCT38 (srb6Δl) were performed with Taq DNA polymerase (Perkin Elmer) in 100 μl of buffer (provided by the manufacturer) supplemented with 1.0 mM MgCl 2 and 200μM dNTP for a total of 25 cycles. Primer concentrations were 0.5 μM with 50 ng of DNA and cycling was at 94°C (1.0 min) , 50°C (1.0 min), and 72°C (2.5 min). Library Construction and Cloninσ Yeast genomic DNA libraries were prepared from strains Z28 (wild type) , Z552 (SRB4-1) , Z553 (SRB5-1) , and Z554 (SRB6-1) . Genomic DNA was isolated partially digested with Sau3A and separated on a 0.7% agarose gel, 6-12 kb fragments were purified by electroelution, and the ends were partially filled in with d(AG)TP using Klenow. The URA3 centromeric plasmid pCT3 was digested with Xhol, and the ends were partially filled in with d(CT)TP to make them compatible with the ends of the Sau3A digested genomic DNA. Following ligation, DH5α cells made competent by the method of Hanahan (Hanahan, D., et al . , Meth. Enzvmol. 204:63-113 (1991)) were transformed. Libraries contained approximately 150,000 individual recombinants with an average insert size of approximately 10 kb. Subgenomic DNA libraries were prepared from pCT4 (SRB4) , pCT14 (SRB5-1) , and pCT26 (SRB6-1) in a manner similar to that described above for the genomic DNA libraries. Plasmid insert DNA was partially digested with Sau3A and separated on a 1.5% agarose gel, and 1-3 kb fragments were purified by gene clean (BIO 101) , and the ends were partially filled in with d(AG)TP using Klenow. Fragments were ligated with pCT3 prepared as described above and transformed into DH5α cells. Subgenomic libraries contained approximately 20,000 individual recombinants with an average insert size of 2 kb. Genomic clones of SRB4-1 (pCT8) . SRB5-1 (pCT14) , and SRB6-1 (pCT26) were isolated by transformation of the respective genomic library into Z551, plating to SC-Ura medium and placing plates at 12°C following a 12 hr recovery period at 30°C. Approximately 1 in 2000 primary transformants was able to grow at 12°C. For each library transformed, the genomic clone was isolated by the method of Hoffman, C.S. and Winston, F., Gene 57:267-272 (1987), from over 12 Ura colonies able to grow at 12°C, and was retested for the ability to suppress the cold-sensitive phenotype of Z551. A genomic clone of SRB4 (pCT4) was isolated from the wild-type Z28 library using a recessive SRB4 allele, which has a tight temperature-sensitive phenotype in combination with a CTD truncation allele of 11 repeats. The presence of pCT4 restores a leaky tempera¬ ture-sensitive phenotype to this strain at 38°C. Subgenomic clones made from pCT4 (SRB4) , pCT14 (SRB5- 1) , and pCT26 (SRB6-1) were selected as described above in order to isolate pCT15 and pCT16 (SRB4) , pCT20 (SRB5-1) , and pCT29 (SRB6-1) , respectively. pCT15 and pCT16 differ only in the amount of DNA downstream of SRB4. pCT39 was created from pCT32 in vivo by transforming Z22 with Sacl-Xhol-digested pCT32 DNA and isolating the plasmid from a Ura + transformant that had repaired the plasmid with wild-type SRB5 sequences from the chromosome (Rothstein. 1991) . Similarly, SRB6 was isolated using Ball-Sphl-digested pCT29 DNA to create pCT40. Sequence Analysis Insert DNAs from pCT15, pCT20, and pCT29 (containing SRB4. SRB5-1, and SRB6-1, respectively) were completely sequenced on each strand. Unidirectional deletions were constructed using the Erase-a-Base system (Promega) , and double-stranded sequencing with dideoxynucleotides and Sequenase (US Biochemical) was carried out as described by the manufacturer, using T3 and T7 promoter primers. The suppressing mutations in SRB4, SRB5, and SRB6 were deduced by sequencing using oligonucleotide primers that spanned the entire open reading frames. Positive numbering of the DNA begins with the predicted start site of translation. pCT15 (SRB4) and pCT48 (SRB4-1) were sequenced, and the SRB4-1 mutation was identified as a G to T transversion (nucleotide 1057) that changed amino acid 353 from Gly to Cys.pCT39 (SRB5) and pCT32 (SRB5-1) were sequenced, and the SRB5-1 mutation was identified as a C to T transition (nucleotide 65) that changed amino acid 22 from Thr to lle.pCT40 (SRB6) and pCT29 (SRB6-1) were sequenced, and the SRB6-1 mutation was identified as a C to G transversion (nucleotide 258) that changed amino acid 86 from Asn to Lys. Sequence comparison analysis was performed at the National Center for Biotechnology Information using the BLAST network service. Purification of Recombinant Proteins Purification of SRB2 has been previously described. SRB5 protein was purified from the bacterial strain BL21(DE3) pLysS carrying the plasmid pCT98 in the same manner in which SRB2 was purified. SRB4 and SRB6 were purified as fusions to GST from DH5α carrying pCT107 and pCT116, respectively, according to the method of Smith, D.B. and Johnson K.S., Gene. 67:31-40 (1988) . GAL4 (1-147) -VP16 protein was purified as described by Chasman, D.I., et al., Nature 339:679- 684 (1989) from XA90 carrying pJL2. GST-fusion proteins for CTD affinity purification were purified from DH5o;, carrying pDC127 or pDC130 by affinity chromatography on glutathione-agarose (Sigma) and Ni-NTA agarose (Qiagen) , and then by ion exchange chromatography on SP Sepharose (Pharmacia) to an approximate purity of 95%. In Vi tro Transcription Promoter-dependent in vi tro transcription was carried out as described by Liao, S.M. et al . , Genes. Dev. 5:2431-2440 (1991) . Three hundred nanograms of template were used for promoter-dependent in vi tro transcription reactions, except the template commitment assays, in which 600 ng of template was used per reaction. Optimal activity was obtained using 100 μg of Z561 protein, 150 μg of Z562 protein, and 150 μg of Z563 protein. Transcripts were quantified using a Fuji Bio-image analyzer, promoter-independent transcription assays were performed according to (Nonet, M., et al . , Cell 50:909-915 (1987) . Purified SRB complex used in in vitro transcription assays was purified as described below. Eluate from the second Biorex 70 column was dialyzed in buffer A(50) (buffer A containing 50 MM potassium acetate) and concentrated 4-fold by centrifugation through Centricon 10 filter units (Amicon) . Figure 3A shows the template pGAL4CG " contains a CYC1 TATA element downstream of a single GAL4 binding site that directs expression of a G-less transcript. Figure 3B and 3C shows nuclear extracts made from wild-type cells (Z561) or srb5Δ mutant cells (Z562) were tested for their ability to synthesize specific transcripts from the pGAL4CG " template in the presence or absence of recombinant SRB2 (250 ng) and/or SRB5 (250 ng) . Transcription reactions were carried out in the absence (B) or presence (C) of recombinant GAL4- VP16 (150 ng) . The film shown in (B) was exposed five times longer than that in (C) . Quantitation of the results indicates that the level of specific transcripts produced by srb5Δ extracts is 50-fold less than that produced by wild-type extracts in the absence of added SRB proteins. Addition of both SRB2 and SRB5 to srb5Δ extracts restored transcript levels to approximately 40% of those observed in wild-type extracts. Figure 3D and 3E shows nuclear extracts made from wild-type cells (Z561) or srb2Δl, srb5Δl mutant cells (Z563) were tested for their ability to synthesize specific transcripts from the pGAL4CG " template in the presence or absence of recombinant SRB2 (250 ng) and/or SRB5 (250 ng) . Transcription reactions were carried out in the absence (D) or presence (E) of recombinant GAL4-VP16 (150 ng) . The film shown in (D) was exposed five times longer than that in (E) . Quantitation of the results indicates that the level of specific transcripts produced by srb2Δ, srb5Δ extracts is 50- fold less than that produced by wild-type extracts in the absence of added SRB proteins. Addition of both SRB2 and SRB5 to srb2Δ, srb5Δ extracts restored transcript levels to approximately 40% of those observed in wild-type extracts. Template Commitment Assay As shown in Figure 4A and 4B, are essential for efficient preinitiation complex formation. (A) SRB2 is necessary for formation of stable preinitiation complex. The templates used in the template commitment assay each contained in a CYC1 TATA element downstream of a single GAL4-binding site that directs expression of a G-less transcript. The long (L) template (pGAL4CG) contained in a G-less cassette of 400 nt, and the short (S) template (pCT108) contained a G-less cassette of 300 nt. The two templates were incubated separately with nuclear extracts from srb2Δl, srb5Δl cells (Z563), SRB5 (250 ng) and GAL4-VP16 (150 ng) . A limiting amount of SRB2 protein (25 ng) was added to 1 of the 2 reaction mixtures. After a 60 min preincubation, the 2 reactions were mixed together, and aliquots were removed at 10 min intervals and transcriptionally competent complexes were assayed by the addition of nucleoside triphosphates. The reactions were terminated after 7 min to minimize reinitiation. Control experiments are shown in lanes 1-4. Extracts from srb2Δl, srbδΔl cells were preincubated with SRB2, SRB5 and GAL4-VP16 along with short and long template, individually (lanes 1-2) or in combination (lane 3) . In lane 4, both templates were incubated in the presence of SRB5 and GAL4-VP16 but in the absence of SRB2. After mixing of preincubation reactions, aliquots were removed and nucleoside triphosphates were added at the indicated times (lanes 5-12) . (B) SRB5 is necessary for formation of a stable preinitiation complex. The template commitment assay was performed as in (A) , except that preincubations were performed in the presence or absence of limiting amounts of SRB5 (75 ng) and excess of SRB2 (250 ng) . Purification of SRB Complex An outline of the purification scheme is shown in Figure 5A. Yeast strain BJ926 (Buchman, A.R. et al . , Mol. Cell. Biol. 8:5086-5099 (1988)) was grown at 30°C to ODgoo of 4.0-4.5 in 1 x YNB medium (0.15% Difco yeast nitrogen base, 0.5% ammonium sulfate, 200 μM inositol, 2% glucose) . The level of the SRB complex appeared to be elevated in cells grown in minimal medium, and this observation was exploited to facilitate purification of the TBP containing SRB complex. Cells were collected by centrifugation and washed in ice cold buffer (20 mM HEPES KOH (pH 7.5), 10% glycerol, 50 mM potassium acetate, 1 mM dithiothreitol (DTT) , and 1 mM EDTA) . Whole-cell extract was prepared from 480 g of cell paste as described by Sayre, M.H. et al. J. Biol. Chem. 267:23376-23382 (1992). Protease inhibitors used where indicated were: 1 mM phenylmethylsufonyl fluoride, 2 mM benzamidine, 2 μM pepstatin A, 0.6 μM leupeptin, 2 μg/ml chymostatin. 5 μg/ml antipain HCl (Sigma) . During purification, the SRB complex was monitored by Western blot using antibodies to SRB2, SRB4, SRB5, and SRB6. Silver staining of gels was performed as per Blum, H. et a . Electrophoresis 8:93-99 (1987), with minor modifications. The gels were fixed for a minimum of 4 hr, and the impregnation with silver nitrate was performed for 40 min. Whole-cell extract (8 g of protein in 390 ml) was diluted 1:5 in buffer A (20% glycerol, 20 mM HEPES KOH (pH 7.5) , 1 mM DTT, 1 mM EDTA. and protease inhibitors) . The extract was loaded onto a 5 cm x 17 cm Biorex 70 (Bio Rad Laboratories) column at a flow rate of 5 ml/min. The column was washed with buffer A (100) until no further protein could be eluted from the column. The column was then eluted with step washes of buffer A (300) and buffer A (600) . The SRB complex eluted in the 600 mM potassium acetate step. The Biorex 70 (600) fraction (250 mg in 120 ml) was diluted 1:6 with buffer B (20% glycerol, 20 mM Tris-acetate (pH 7.9), 1 mM DTT, 1 mM EDTA. 0.01% Nonidet P-40, and protease inhibitors and was loaded onto a 2.5 cm x 8.5 cm diethylaminoethyl (DEAE) - Sephacel column (Pharmacia) at a flow rate of 4 ml/min. The column was washed extensively with buffer B (100) and then eluted with step washes of buffer B (400) and buffer 6 (650) . The SRB complex eluted from this column in the 400 mM potassium acetate step. The DEAE-Sephacel (400) fraction (48 ml) was dialyzed into buffer C (20% glycerol, 10 mM potassium phosphate (pH 7.7) , 100 mM potassium acetate, 1 mM DTT, 0.25 mM EDTA, 0.01% Nonidet P-40, and protease inhibitors) . The dialysate was spun in a Sorvall SS34 rotor at 10,000 rpm for 20 min and the supernatant (50 mg of protein in 50 ml) was loaded onto a 1.5 cm x 6.5 cm Bio-Gel HTP Hydroxylapatite at a flow rate of 1 ml/min. The column was washed with 20 ml of loading buffer and eluted with a 120 ml linear gradient of buffer C to buffer D (buffer D is identical to buffer C except that it contains 300 mM potassium phosphate (pH 7.71) . The SRB complex eluted from this column in a peak corresponding to 68-112 mM potassium phosphate. The 20 ml of eluate from the Bio-Gel HTP (Bio-Rad Laboratories) was dialyzed against buffer E (same as buffer B except 0.25 mM EDTA) containing 100 mM potassium acetate. The dialyzed material was spun in a Sorvall SS34 rotor at 10,000 rpm for 20 min. and the supernatant (11 mg protein in 20 ml) was loaded onto a Mono Q HR 5/5 fast protein liquid chromatography column (Pharmacia) and eluted with a 15 ml linear gradient from buffer E (100) to buffer E (2000) at a flow rate of 0.5 ml/min. The SRB complex eluted from this column at 0.95 M potassium acetate. Peak fractions containing SRB activity were diluted 1:6 with buffer F (same as buffer A except 0.25 mM EDTA) . This material (1.1 mg of protein in 10 ml) was loaded onto a Mono S HR .5/5 FPLC column (Pharmacia) and eluted with a 10 ml gradient from buffer F (100) to buffer F (1000) at a flow rate of 0.5 ml/min. The SRB complex eluted from this column at 450 mM potassium acetate. This material (0.6 mg of protein in 8 ml) was diluted 1:4 in buffer E (0) and loaded onto a 1.5 um x 1.5 cm DEAE-Sephacel column and eluted with a 20 ml gradient from buffer E (100) to buffer E (1000) at a flow rate of 0.3 ml/ min. The SRB complex eluted from this column at 400 mM potassium acetate. (Further chromatography revealed that this material was approximately 90% pure.) This material (0.5 mg of protein in 2 ml) was diluted 1:4 in buffer F (0) and loaded onto a 1.5 cm x 1 cm Biorex 70 column and was eluted with a 10 ml gradient from buffer F (100) to buffer F (1000) . The SRB complex eluted from this column at 600 mM potassium acetate and was approximately 95% pure. The total yield of the SRB complex was 0.5 mg, and purification was estimated to be 10,000-fold. The SRB complex was subjected to gel filtration chromatography in buffer F (400) on a Superose 6 HR 10/30 FPLC column (Pharmacia) . The estimated molecular size of the SRB complex was determined by extrapolation of a calibration curve performed with thyroglobulin (669 kd) , apoferritin (443 kd) , bovine serum albumin (132 kd, 66 kd) and carbonic anhydrase. CTD Affinity Purification Whole-cell extracts were prepared by adding 1.61 of 4% glucose to 800 g of Red Star dry yeast, incubating the mixture at room temperature for 45 min, and adding 800 ml of disruption buffer (1.2 M ammonium sulfate, 0.16M K-HEPES (pH 7.3), 4 mM DTT, and protease inhibitors [as in the conventional purification above] ) . Aliquots (200 ml) were frozen dropwise in liquid nitrogen and blended for 5-10 min in a Waring blender. After thawing at 55 ° C, viscosity was reduced by brief blending. Disrupted cells were centrifuged for 30 min at 12,000 rpm in a Sorvall GSA rotor, and the clarified supernatant was filtered through cheesecloth. One-twentieth volume of a 10% solution of Polymin P was added, the extract was incubated on ice for 30 min. and the solution was centrifuged for 30 min at 12,000 rpm in a Sorvall GSA rotor. The supernatant was collected and brought to 70% saturation with solid ammonium sulfate and stored at 4 ° C. An aliquot of the suspension was removed from storage and centrifuged at 12,000 rpm in a Sorvall GSA rotor for 30 min. The pellet was resuspended in 1.5 vol of 1 x transcription buffer (Liao, S.M., et al., Genes Dev. 5:2431-2440 (1991)), 1991) plus protease inhibitors and centrifuged at 17,000 rpm in a Sorvall SS34 rotor for 20 min. The supernatant was then diluted 1:6 in 1 x transcription buffer plus protease inhibitors and centrifuged at 12,000 rpm in a Sorvall GSA rotor for 30 min. The supernatant was incubated with 10 g/100 milliliters of cell debris remover (Whatman Labsales) for 15 min. The cell debris remover was removed by centrifugation and filtration. The cleared supernatant was then centrifuged at 40,000 rpm in a Beckman 50.2Ti rotor for 1-2 hr. GST fusion proteins were coupled to Pharmacia activated CH Sepharose according to the manufacturers directions at a concentration of 5 milligrams of protein per milliliter of matrix. The affinity matrices were washed with 6 M guanidine hydrochloride followed by 1 x transcription buffer before use. Twenty milliliters of yeast whole-cell extract were mixed with 1/10 vol of 1 x transcription buffer plus 10% Triton X-100 and applied to 100 μl of either GST-Sepharose or GST-CTD Sepharose. The columns were washed with 20 ml of 1 x transcription buffer plus 1% Triton X-100, followed by 5 ml of 1 x transcription buffer without Triton X-100. Bound proteins were eluted with 1 x transcription buffer containing various concentrations of guanidine hydrochloride. Western Blot Analysis Western blotting of fractions was performed with polyclonal rabbit antisera raised against whole TBP, SRB2, and SRB5 proteins. A GST-SRB4 fusion protein, or a GST-SRB6 fusion protein, by standard methods. RPBl was detected via the CTD with 8WG16 monoclonal antibody ascites fluid (Thompson, N.E. et al., J. Biol. Chem. 164:11511-11520 (1989)). Polyclonal anti-TBP, anti-SRB2, anti-GST-SRB4, and anti-SRB5 antisera were diluted 1:1000. Anti-GST-SRB6 antiserum was diluted 1:200. A 1:1000 dilution of 8WG16 monoclonal antibody ascites fluid was used. In all cases, bands were visualized by secondary probing with alkaline phosphatase conjugate secondary antibodies (Promega) . Figure 5B, left panel, shows a liver-stained SDS- polyacrylamide (15%) gel containing approximately 1 μg of protein from each fraction of the SRB complex purification. Lane 1, whole-cell extract; lane 2, biorex 70; lane 3, DEAE-Sephacel; lane 4, hydroxylapatite; lane 5, Mono Q; lane 6, Mono S; lane 7, DEAE-Sephacel. The positions of RNA polymerase II subunits, SRB proteins, TBP, and additional polypeptides that are candidate subunits of the complex are indicated, M, markers. Figure 5B, right panel, shows Western blot analysis of 1 μg of SRB complex protein from the DEAE- Sephacel fraction loaded onto a SDS-polyacrylamide (15%) gel and probed with antibodies against SRB and TBP proteins. The antibody probes were: lane 1, polyclonal anti-SRB2; lane 2, polyclonal anti-SRB4; lane 3, polyclonal anti-SRB5; lane 4, polyclonal anti- SRB6; and lane 5, polyclonal anti-TBP. Figure 5C shows that Western blot analysis reveals that SRB proteins, RNA polymerase II and TBP coelute from a Mono S column, Semipurified SRB complex (0.8 mg of total protein) from the Mono Q column was loaded onto a Mono S column and eluted with a 0.1-1.0 M gradient of potassium acetate as described in Experimental Procedures. The onput and flow-through material (1/25) and every other eluate fraction (1/50) were analyzed by Western blot for the presence of RPBl, SRB4, SRB5, SRB2, TBP, and SRB6. The SRB complex eluted in a peak corresponding to approximately 0.4 M potassium acetate. Example 3 : RNA Polymerase II Holoenzyme Activity In Vi tro Transcription Activity of the RNA Polymerase II Holoenzyme The RNA polymerase II holoenzyme was purified as described in Example 2. Factor a is required in addition to TBP and the RNA polymerase II complex for in vi tro transcription Sayre, M.H. et al . , J. Biol. Chem. 267:23383-23387 (1992) . Semipurified factor a (300 μg protein in 2 ml) eluted from the Heparin-CL6B column was loaded onto a DEAE-Sephacel column and eluted with a 0.15-1.0 M gradient of potassium acetate. The onput and flow-through and a portion of every other fraction eluting from this column between 0.32 and 1.0 M potassium acetate were analyzed for transcriptional activity and for the presence of polypeptides by SDS-PAGE. Assays were performed using pGAL4G- template (300 ng) , RNA polymerase II complex (1 μg) , recombinant TBP (40 ng) , and 1 μl of the OP, FT, and every other fraction from the column, 2.5 μl of the OP, FT, and every other column fraction was subjected to electrophoresis on a 12% SDS-PAGE gel. Gel was stained with silver using standard protocols. The holoenzyme, factor a, and TBP are sufficient for in vi tro transcription. Transcription reactions were performed using the pGAL4G- template (300 ng) and standard conditions, 30 The holoenzyme (1 μg) , factor a (40 ng) , and recombinant TBP (40 ng) were added to reactions as indicated. This and other figures in this application were prepared from digital replicas of primary data scanned using a UMax UC80 Max Vision digital scanner. The Holoenzyme is a Complex of RNA Polymerase II and Initiation Factors Semipurified holoenzyme that eluted from the Q-Sepharose column (Figure 6A) was loaded onto a Mono S column and eluted with a 0.1-1.0 M gradient of potassium acetate. The onput (OP) and flow-through (FT) and a portion of every other fraction eluting between 0.1 and 0.9 M potassium acetate were analyzed for holoenzyme activity (top panel) . These samples were also analyzed by western blot for the presence of RNA polymerase II and transcription factors (bottom panels) . Top panel, Transcription assays were performed using the pGAL4G- template (300 ng) , Factor a (40 ng) , recombinant TBP (40 ng) , and 1 μl of the OP, FT, and every other fraction from the Mono S column. Bottom panels, one μl of the same fractions were also separated on an SDS-polyacrylamide gel and blotted to nitrocellulose. The blots were probed with polyclonal antibodies specific to the 73 kD subunit of factor b (TFB1) , factor e (SUA7) , SRB2, SRB4, SRB5, and SRB6 and monoclonal specific to the largest subunit of RNA polymerase II (RPBl) . Figure 6B shows the polypeptide composition of RNA polymerase holoenzyme. One microgram of purified holoenzyme was subjected to SDS-PAGE and stained with silver. Western blots of purified holoenzyme were performed on samples run on adjacent lanes of the gel with antiserum used in Figure 6A to identify subunits of the SRB complex. Proteins in the holoenzyme preparation that correspond in size to subunits of RNA polymerase II SRB proteins, or subunits of initiation factors are indicated. The sizes of protein molecular weight standards are indicated in kD. Figure 6C shows coimmunoprecipitation of holoenzyme components with SRB5. Fifteen micrograms of the purified RNA polymerase II were diluted in 0.5 ml of transcription buffer containing potassium acetate instead of potassium glutamate, 0.01% NP40, and 0.1 mg/ml BSA. One microgram of affinity purified anti-HSP70 or anti-SRB5 antibodies, and five micrograms of recombinant SRB2 or SRB5 protein were added as indicated. Immunoprecipitated material was analyzed by western blot as indicated in (B) for the presence of transcription factor subunits and RNA polymerase II. Figure 6D shows quantitation of holoenzyme components. Samples of whole cell extract, nuclear extract, and purified holoenzyme together with standard amounts of purified RNA polymerase II and recombinant transcription factor subunits were quantitated by western blotting. Each gel contained the following: 25 μg yeast whole cell extract (lane 1) , 25 μg yeast nuclear extract (lane 2) , 1 μg purified holoenzyme (lane 3), and 0.2 μg purified holoenzyme (lane 4) . The gels also contained purified standard proteins in lanes 5-7 in following amounts: 8, 40, and 200 ng RNA polymerase II; 4, 20, and 100 ng 6His-tagged factor e (SUA7) ; 3.2, 16, and 80 ng SRB2; 4, 20, and 100 ng SRB5; 3.2, 16, and 80 ng TOA1; 3.2, 16, and 80 ng TBP. Epitope-tagged SRB2 and 6His-tagged factor e (SUA7) used in this analysis exhibit slightly lower mobility on gels than their untagged counterparts. The RNA polymerase II CTD in the holoenzyme is the hypophosphorylated form (IIA) . Figure 6E shows a summary of holoenzyme components. The amount of each holoenzyme component in 1 μg of the holoenzyme was determined by comparison with standard amounts in (D) . Taking the molecular weight of each component into account, the stoich- iometry of each factor per RNA polymerase II molecule is presented. Transcription by the Holoenzyme is Stimulated bv GAL4- VP16 As shown in Figure 7A, transcription reactions were performed using either a template containing a CYCI TATA element that directs transcription of a G-less cassette (-GAL4 Site template) or a template that contained in addition a single consensus DNA binding site for the GAL4 protein upstream of the TATA element (+GAL4 Site template) . GAL4-VP16 (150 ng) was added to reactions as indicated. Top panel, reactions were performed with the holoenzyme (1 μg) , factor a (40 ng) , recombinant TBP (40 ng) , and each template (100 ng) as indicated. Bottom panel, reactions were performed with yeast nuclear extract protein (150 μg) . Transcription in reactions containing nuclear extract is stimulated 10-fold by GAL4-VP16. Transcription by the holoenzyme is stimulated 5-fold by GAL4-VP16. The +GAL4 site template is pGAL4G-. The GAL4 site template is pSL187. The exposure in the top panel was 5 times longer than the exposure in the bottom panel. Levels of transcript were quantitated using a Fuji Bio-image Analyzer. As shown in Figure 7B, reactions were performed with the holoenzyme as detailed above except 225 ng of template, linearized by digestion with PvuII restriction endonuclease, was used. This exposure was 3 times longer than the holoenzyme panel in (A) . Example 4: SRB7, SRB8. SRB9. SRBIO. SRB11 Genes and Their Encoded Proteins Yeast strains and plasmids are listed in Table 5 and 6, respectively. able 5. Yeast Strains Table 6 Plasmids Plasmid Description SRB7 pCH2 SRB7 (6.7 kb) URA3 CEN. PCH7 SRB7 (2.0 kb) URA3 CEN. PCH36 srb7-l URA3 CEN. pCH3 SRB7 in pET-3a (Studier and Moffat, 1986) pCH46 srb7Δl: :URA3hisG in pSP72 (Promega) . SRB8 pSL301 SRB8 (9.0 kb) URA3 CEN. pSL311 SRB8 (6.0 kb) URA3 CEN. pSL307 SRB8 (encoding aa 868 to 1226) in pET-3a (Studier and Moffat, 1986) . pSL315 srbβΔl: :URA3hisG in pBSIISK (+) (Stratagene) . SRB9 pCH47 SRB9 (7.3 kb) URA3 CEN. pCH64 SRB9 (encoding aa 45 to 501) in pGEX-I (Smith and Johnson, 1988) . pCH66 SRB9Δ1: :URA3hisG in pSP72 (Promega) . RPB2 pSL401 RPB2 (10 kb) URA3 CEN. pSL411 rpb2-551 URA3 CEN. Yeast media was prepared as described (Thompson, C. M. , et al., Cell 73:1361-1375 (1993) . Yeast transformations were done using a lithium acetate procedure (Schiestl and Gietz, 1989) . Plasmid shuffle techniques were performed as described by Boeke, J. , et al . Meth. Enzvmol. 154:164-175 (1987) using 5-fluoroorotic acid (5-FOA) as a selective agent against URA3 plasmids. Plasmids were recovered from yeast as described by Hoffman, C.S. and Winston, F., Gene 57:267-272 (1987) . Growth assays were performed by suspending similar numbers of cells in water and transferring equal volumes to agar plates with a 48-prong apparatus. To reduce flocculation of some strains, cells were first washed in 100 mM EGTA, 10 mM Tris-HCl 7.5. Extragenic suppressors of the cold sensitive phenotype of Z551 were isolated as previously described. Dominant and recessive suppressors were identified by mating to Z26, selecting against the presence of pRP112 using 5-FOA and assaying growth at 12°C on YEPD. Diploids able to grow at 12°C contained a dominant suppressor. Diploids unable to grow at 12°C contained a recessive suppressor. Yeast strains of the opposite mating type of approximately half of the dominant suppressors and half of the recessive suppressors were generated by inducing a mating type switch by expression of the HO gene placed on a plasmid under the control of a galactose inducible promoter. Random spore analysis of the dominantly suppressing mutations was used to determine if two independent isolates were likely to contain mutations in the same gene. Haploids were mated to each other, each containing the CTD truncation mutation rpblΔl04 and an independently isolated SRB mutation, to form diploids. These diploids were sporulated on plates and a small quantity of spores scraped off and shaken overnight at 30°C in 0.5 ml 30 mM β-mercaptoethanol and 100 ng/ml Zymolase 100 T (ICN) . 0.5 ml of 1.5% NP-40 and 0.4 g glass beads were added and the mixture held on ice for 15 min. The suspension was then vortexed 3 min, held on ice 5 min, vortexed 2 min, and the glass beads allowed to settle for 10 min at room temperature. The supernatant was removed, spun 2 min, the pellet washed once in water, then resuspended in water and a portion plated onto YEPD. Approximately fifty of the haploid offspring were assayed for their ability to grow at 12°C. If all haploids were able to grow at 12°C then the two SRB isolates were assumed to contain mutations in the same gone. Genetic complementation of the recessive alleles involved mating haploids to each other, each containing the CTD truncation mutation rpblΔl04 and an independently isolated srb mutation, to form diploids and assessing the ability of these diploids to grow at 12°C. Diploids able to grow at 12°C were assumed to contain srb mutations in the same gene. Genomic clones of each complementation group were used to confirm the identity of each member of the complementation group and to identify additional members. Cells containing the CTD truncation mutation rpblΔl04 and a recessive srb allele were unable to grow at 12°C and on pyruvate media when transformed with the corresponding wild-type SRB allele. Deletions of SRB7, SRB8 and SRB9 were created by a single step disruption method. Z558 was transformed with the desired DNA fragment and plated on SC-Ura media. Southern analysis was used to confirm that a single copy of the desired SRB gene had been deleted. The diploid was sporulated and tetrads dissected (>20) on YEPD plates and scored for nutritional auxotrophies and growth at a variety of temperatures. Z575 was created by transformation with the srb7Δl: :URA3hisG fragment from pCH46. Two or less spores from each tetrad were viable and these spores were uracil auxotrophs, indicating that SRB7 is essential. Z576 was created by transformation with the srbδΔl: :URA3hisG fragment from pSL315 and Z577 was created by transformation with the srb9Δl: :URA3hisG fragment from pCH66. In each case segregants scored 2:2 for uracil prototrophy and all uracil prototrophs exhibited mild cold-sensitive, temperature-sensitive, and slow growth phenotypes, indicating that SRB8 and SRB9 deletion strains are conditionally viable. srbδAΔl and srb9Δl strains are also flocculent as are the suppressing isolates of SRB8 and SRB9. Strains containing unmarked deletions of SRB8 and SRB9 were created by selecting for excision of the URA3 gene by growth on 5-FOA (Alani, E. et al . , Genetics 116:541-545 (1987)). The influence of SRB2 and SRB8 alleles on growth phenotypes of RNA polymerase II CTD truncation mutants was tested as follows. Strains containing combinations of SRB2 or SRB8 alleles and CTD truncation alleles were assayed for growth on YEPD medium at 12°C, 30°C, and 38°C and on SC medium containing pyruvate as a sole carbon source. The degree of CTD truncation is shown for each mutant on the horizontal axis, and the plasmid carrying each CTD truncation allele is indicated (i.e., pN51) . The phenotypes exhibited by each of the CTD truncation mutants in a wild-type, srb2Δl, SRB2-1, or srbδΔl background are shown on left. Nonviable strains (N) are indicated by a dashed line, conditional strains (C) that were extremely sensitive to high (38°C) and low (12°C) temperatures and failed to grow on pyruvate media are indicated by a thin solid line, and viable (V) strains that exhibit nearly wild-type growth characteristics under all conditions tested are indicated by a heavy solid line. Viable/conditional srbδΔl strains (V/C) were able 'to grow at low temperatures and on pyruvate medium but were sensitive to high temperatures and are indicted by a solid line. Not every CTD truncation allele was tested in every background, but for each background the phenotypic boundaries are well established. DNA methods DNA manipulations were performed according to Sambrook et al . , Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory 1989) . Site-directed mutagenesis was performed as described in Kunkel, T.A., et al., Meth. Enzvmol. 154:367-382 (1987). PCR amplifications to produce pCH45 (srb7Δl) , pSL315 (srb8Δl) , and pSL307 (SRB8 in pET-3a) were performed with Taq DNA polymerase (Perkin Elmer) in lOOλ of buffer (provided by the manufacturer) supplemented with 200 μM dNTP for a total of 25 cycles. Primer concentrations were 0.5 μM with 50 ng of DNA and cycling was at 94°C (1.0 min), 50°C (1.0 min) and 72°C (2.5 min) . Cloning and Sequence analysis Genomic clones of SRB7 (pCH2) , SRB8 (pSL301) , SRB9 (pCH 7) , and RPB2 (pSL401) were isolated by transformation and complementation of Z567, Z568, Z569, and Z570, respectively. pCH36 was created from pCH7 in vivo by transforming Z567 with linearized pCH7 lacking SRB7 coding DNA and isolating the plasmid from a Ura + transformant which had repaired the plasmid with the mutant srb7-l sequences from the chromosome. Similarly, rpb2-551 (pSL411) was isolated from Z570 using pRP212. SRB7 and SRB9 were completely sequenced on each strand using genomic DNA from pCH7 and pCH47, respectively. Unidirectional deletions were constructed using the Erase-a-Base system (Promega) and double stranded sequencing with dideoxynucleotides and Sequenase (US Biochemical) was carried out as described by the manufacturer using T3 and T7 promoter primers. Gaps in the sequence were filled in by sequencing with internal oligonucleotide primers. The suppressing mutations in SRB7 and RPB2 were deduced by sequencing using oligonucleotide primers that spanned the entire open reading frames. Sequence comparison analysis was performed at the National Center for Biotechnology Information using the BLAST network service. A restriction map of a 2.0 kb DNA fragment from pCH7 containing the SRB7 gene was determined. The entire coding region of SRB7 was replaced with a 5.5 kb DNA fragment containing the URA3 and kanamycin genes flanked by direct repeats of Salmonella hisG DNA to create the deletion allele srb7Δl: :URA3hisG. The predicted 140 aa sequence of the SRB7 protein is shown in Figure 9. Positive numbering of the DNA begins with the predicted start site of translation. The srb7-l mutation is a G to A transition (nt 61) that changes aa 21 from Ala to Thr. A restriction map of a 6.0 kb DNA fragment from pSL311 containing the SRB8 gene was also determined. Approximately 500 bp upstream of SRB8 there is an inversion, relative to the genomic DNA used to sequence that region of chromosome III, encompassing greater than 2 kb. The entire coding region of SRB8 was replaced with a 5.5 kb DNA fragment containing the URA3 and kanamycin genes flanked by direct repeats of Salmonella hisG DNA to create the deletion allele srb8Δl: :URA3hisG. The DNA sequence SRB8, with its predicted amino acid sequence is shown in Figure 10A and 10B. A restriction map of a 7.3 kb DNA fragment from pCH47 containing the SRB9 gene was also determined. Most of the coding region of SRB9 was replaced with a 5.5 kb DNA fragment containing the URA3 and kanamycin genes flanked by direct repeats of Salmonella hisG DNA to create the deletion allele srb9Δl: :URA3hisG. Figure 11A, 11B and 11C shows the sequence of the 7.3 kb DNA fragment containing the SRB9 gene. The predicted 1420 aa sequence of the SRB9 protein is shown below the sequence of the gene. The DNA sequences and their predicted amino acid sequences for SRB10 and SRB11 are shown in Figures 12 and 13 respectively. Purification of recombinant proteins Recombinant proteins were purified for generating polyclonal antibodies in rabbits. SRB7 and a portion of SRB8 (amino acids 868 to 1226) were purified from the bacterial strain BL21 (DE3) pLysS (Studier and Moffatt, 1986) carrying the plasmids pCH34 and pSL307, respectively, in the same manner SRB2 was purified. A portion of SRB9 (amino acids 45 to 501) was purified as a fusion to glutathione-S-transferase from DH5α carrying pCH64 according to the method of Smith, D.B. and Johnson K.S., Gene. 67:31-40 (1988). In Vi tro transcription and Western blot analysis In vi tro transcription assay for holoenzyme activity was performed as described above. Western blotting was performed by standard methods. RPBl was detected via the CTD with 8WG16 monoclonal antibody ascites fluid (Promega) . Polyclonal rabbit anti-SRB2, anti-GST-SRB4, anti-SRB5, anti-GST-SRB6, anti-SRB7, anti-SRB8 (aa 868 to 1226) , and anti-GST-SRB9 (aa 45 to 501) antiserum were used to detect the SRBs. In all cases, bands were visualized by secondary probing with alkaline phosphatase conjugate secondary antibodies (Promega) . Figure 15A and 15B shows that SRB2 and SRB4-SRB9 are components of an RNA polymerase II holoenzyme. (A) Semipurified holoenzyme that eluted from the Q-sepharose column as described in Example 3 was loaded onto a Mono S column and eluted with a 0.1-1.0 M gradient of potassium acetate. The onput (OP) and flow-through (FT) and a portion of every other fraction eluting between 0.1 and 0.9 M potassium acetate were analyzed for holoenzyme activity (top panel) . These samples were also analyzed by Western blot for the presence of RNA polymerase II and SRB proteins. This figure was prepared from digital replicas of primary data scanned using a UMAX UC840 Max Vision digital scanner. (B) Polypeptide composition of RNA polymerase II holoenzyme. One microgram of purified holoenzyme was subjected to SDS-PAGE and stained with silver. Proteins in the holoenzyme preparation that correspond in size to subunits of RNA polymerase and SRB proteins are indicated. The .sizes of protein molecular weight standards are indicated in kd. Example 5: General Requirement for RNA Polymerase II Holoenzyme In Vivo PCR mutagenesis was performed as described by D.W. Leung, E. Chen, D.V. Goeddel, Technique. 1:11 (1989) . The plasmid pCT127 (SRB4 LEU2 CEN) contains a unique Ndel site at the SRB4 ATG and a unique Xbal site following the SRB4 stop codon, both created by site- specific mutagenesis (T.A. Kunkel, J.D. Roberts, R.A. Zakour, Meth. Enzvmol. 154:367 (1987)). PCR of SRB4 from pCT127 with oligonucleotides flanking the ORF was performed in buffer containing 0.1 mM, 0.2 mM, and 0.4 mM Mn 2+ . Reactions were pooled, DNA digested with Ndel- Xbal, ligated with Ndel-Xbal digested pCT127 vector fragment, and transformed into DH5c_. Approximately 30,000 transformants were obtained. Plasmid shuffle techniques were performed as described by J. Boeke, J. Truehart, B. Natsoulis, G.R. Fink, Meth. Enzvmol. 154:164 (1987), using 5- flouroorotic acid (5-FOA) as a selective agent against URA3 plasmids. Genetic manipulations of yeast were performed as previously described. DNA molecules containing LEU2 and mutagenized SRB4 genes were transformed into a yeast strain (CTY182) deleted for the chromosomal copy of SRB4, but carrying a URA3 centromeric plasmid encoding a wild-type copy of the gene. Approximately 20% of the transformants were unable to grow in the presence of 5-FOA, indicating a lethal mutation in the LEU2 plasmid-borne SRB4 gene. Approximately 0.5% of the transformants were able to grow on 5-FOA plates at 30°C but not at 37°C, indicating a ts allele in the LEU2 plasmid-borne SRB4 gene. The LEU2 plasmids from these transformants were recovered and reintroduced in CTY182 to verify the ts phenotype. The plasmid pCT181 contains the srb4-l38 mutant allele. Total RNA from cells was isolated using hot acidic phenol extraction (F.M. Ausubel et a . , Ed., Current Protocols in Molecular Biology (John Wiley and Sons, New York, (1993)) . RNA was quantified by absorbance at 260 nm and the integrity of the RNA confirmed by ethidium bromide straining of RNA in agarose gels. SI nuclease protection assays were carried out with 5-30 ug of RNA and DED1, HIS3, TRP3, rRNA and tRNA* oligonucleotide probes as previously described (Cormack _ Struhl) . The sequences for the other oligonucleotide probes are: ACT1 (GGAAGAGTACAAGGACAAAACGGCTTGGATGGAAA CGTAGAAGGCATTCCA) (SEQ ID NO: 30), CDC7 (GGGGCTACTCTC GAAGATCCCGTCATTATGTACAGCAGGTTGAGCATGCCT) (SEQ ID NO: 31) , MET 19 (GCCTTACCGGCACGCATCATGATGGGGACGCCCTCCCAACGCTCGAC ACTT) (SEQ ID NO: 32), RAD23 (GCAGTGGCTGCAGGAGCTGCAG AAGCATCGGTACTGGGGGATGCAATCCA) (SEQ ID NO: 33), STE2 (GTCGACGGGTTCAACTTCTCCCTCTTTGTAACTTGCATCAGCAAACGGATGACA ) (SEQ ID NO: 34) , AND TCM1 (GGAGTGTCAACAACGGTGACAGCTTCGAC AACTTCACGCTTGTGGTGAGCT) (SEQ ID NO: 35) . Oligonucleotides are written in the 5' 3' direction and contain 6 residues at their 3' ends that are not complementary to the RNA, permitting distinction between bands due to appropriate RNA-DNA hybrids and undigested probe. Example 6 ; Cloning and Sequencing of hSRB7 XREF db was used to screen the dbEST for expressed sequence tags similar to ySRB7 (Boguski, M.S. et al., Jr. Science. 265:1993-1994 (1994)) . Overlapping sequences (Genbank accession numbers H08048, R19473, and F13227) were identified as encoding a potential ySRB7 homolog. Sequences derived from the tags were used to design primers for amplifying the hSRB7 gene. Vent DNA polymerase (New England Biolabs) was used according to the manufacturer's directions to amplify a hSRB7 probe from a human peripheral blood lymphocyte cDNA library constructed in 1YES (Elledge, S.J. et al . , Proc. Natl. Acad. Sci. USA. 88:1731-1735 (1991) ) . The probe was used to isolate a full length clone of hSRB7 from the same library by standard techniques. (Ausubel, F.M., current Protocols in Molecular Biology (Current Protocols, 1994)). The DNA sequence of hSRB7 was determined with Sequenase (US Biochemical) according to the manufacturer's directions. The initiating ATG was assigned based on homology to ySRB7. ySRB7 and hSRB7 are 35% identical and 58% similar. ySRB7 and hSRB7 are more similar to each other than to any other sequenced genes. ySRB7 and hSRB7 were aligned using the program BESTFIT (Genetics Computer Group, Inc.) . A gap weight of 1.0 and a length weight of 0.1 were used. Using the hSRB7 sequence as a query, a BLAST search of the National Center for Biotechnology Information non-redundant protein database retrieved ySRB7 with a smallest sum probability of 6.4X10-6 (Altschul, S.F. et al . , J. Mol. Biol.. 215:402-410 (1990)). No other significant matches were reported. A BLAST search with ySRB7 did not retrieve any significant matches other than ySRB7 itself. Example 7: Complementation of a ySRB7 deletion with vSRB7-hSRBv Chimeras The appropriate regions of ySRB7 were amplified by PCR with Vent DNA polymerase (New England Biolabs) according to the manufacturer's directions. The appropriate regions of hSRB7 were similarly amplified except that an 18 bp region of homology to the appropriate segment of ySRB7 was appended to the 3' primer used to amplify each fragment. The PCR fragments were gel purified, combined and amplified again with primers hybridizing to the N-terminus of hSRB7 and the C-terminus of ySRB7. The appropriate PCR fragments were gel purified, amplified again and cloned into the Bglll site of the yeast expression vector DB20LBgl2 (a gift of L. Guarente) The chimeras are full length ySRB7 (residues 1-140) ; hSRB7 (1-20) -ySRB7(21-140) ; hSRB7(1-77) -ySRB7(82-140) ; hSRB7 (1-117) -ySRB7(129-140) ; and full length hSRB7(1-144) . Plasmids expressing the chimeras were shuffled into the strain EGY112 (MATa ura3-52, his3D200, leu2-3,112, SRB7D1 (pCH7: SRB7 URA3 CEN) by LiOAc transformation and selection on 5-fluoroorotic acid (Boeke, J.D. et al., Methods Enzvmol. 154:164-175 (1987); Schiestl, R.H. and Gietz, R.D., Curr. Genet. 16:339-346 (1989)). Three independent clones were tested for each chimera, and the sequence of at least one clone for each chimera was confirmed by DNA sequencing. Example 8: hSRB Binding to the CTD A BioRex 70 fraction containing SRBs prepared from a wild-type S288C strain was mixed with an equal volume of Buffer A(20 mM K-HEPES pH 7.6, 1 mM EDTA, 20% glycerol, 1 mM DTT, 0.5 mM PMSF, 1 mM benzamidine, 0.5 uM pepstatin, 0.15 uM leupeptin, and 1 ug/ml chymostatin) + 2% Triton X-100 and applied to a preclearing column. The precleared extract was applied to a GST or GST-CTD column (Hengartner, C.J. et al. , Genes and Development. 9:897-910 (1995); Thompson, C . et al . , Cell. 73:1361-1375 (1993)). Columns were washed sequentially with Buffer A + 300 mM KOAc+1% Triton X-100 and Buffer A + 300 mM KOAc and then eluted with Buffer A + 300 mM KOAc + 4 M Urea. Eluates were precipitated with TCA and separated by SDS-polyacrylamide gel electrophoresis on 4-20% gradient gels (BioRad) . Western blotting was performed with as described Hengartner, C.J. et al . , Genes and Developmen . 9:897-910 (1995). Example 9: hSRB7 Association with RNA Polymerase IT pEG121 was constructed by amplifying amino acids 65 to 92 of hSRB7 by PCR with Vent DNA polymerase (New England Biolabs) according to manufacturer's directions and inserting the PCR product into the BamHI and Sail sites of pGEX-4T-3 (Pharmacia Biotech) . The resulting GST-hSRB7 C-terminal fragment fusion was purified as described [Smith, 1988 #1936] and used to immunize female New Zealand white rabbits with RIBI adjuvant (RIBI ImmunoChem Research, Inc.) according to manufacturer's directions. In HeLa and COS cell extracts, antibody raised against hSRB7 recognizes a protein with a relative mobility of 16 kD. This relative mobility is consistent with hSRB7's predicted molecular weight of 15.7 kD. Additional evidence that the antibody specifically recognizes hSRB7 comes from experiments with COS cells transiently transfected with an hSRB7 expression construct. When probed with antibody raised against hSRB7, Western blots of extracts from these cells contain a 16 kD band whose signal is twenty-fold greater than in extracts from control cells (data not shown) . We conclude from these experiments that the anti-hSRB7 antibody specifically recognizes hSRB7 in Western blots. The antibody directed against human SRB7 recognizes a comigrating 16 kD band in calf thymus extracts. Because of the high degree of conservation among mammalian transcription factors, it is reasonable to believe this 16 kD protein represents bovine SRB7. A HeLa whole cell extract (Manley, J.L. et al . , Proc. Natl. Acad. Sci. USA. 77:3855-3859 (1980)) was applied to a CTD column as above. The blot was probed with a 1:250 dilution of an antisera raised against the C-terminal fragment of hSRB7. Aliquots of frozen calf thymus (1 kg) were placed in a nylon bag (The North Face) and broken with a hammer. The frozen pieces were added to 2 1 of 50 mM Tris-OAc pH 7.8, 10 mM EDTA, 10 mM EGTA, 5% glycerol, 0.2 mM DTT and protease inhibitors as in Buffer A. Aliquots of the calf thymus were mixed in a Waring blender for 2 minutes each. The mixed calf thymus was pooled and aliquots were blended for an additional 2 minutes. The blended thymus was spun at 5,000 r.p.m. for 30 min. in a Sorvall RC3B centrifuge. The supernatant was decanted through Miracloth (CalBiochem) , centrifuged and decanted through Miracloth again. After the addition of 29.1 g of ammonium sulfate/100 ml of supernatant, the suspension was stirred for 15 minutes at 4C and centrifuged at 6,000 r.p.m. for 30 minutes in an RC3B. The supernatant was decanted, and the pellet was resuspended in Buffer D (50 mM Tris-OAc pH 7.8, 0.1 mM EDTA, 5 % glycerol ) such that the conductivity was equal to that of Buffer D + 300 mM ammonium sulfate. 5.5 ml of 10% polyethylenimine was added per liter of extract and the extract was stirred for 10 minutes at 4C. The extract was centrifuged at 8,000 RPM for 30 minutes in a Sorvall GS3 rotor. The supernatant was decanted and Buffer D was added so that the conductivity was equal to that of Buffer D + 150 mM ammonium sulfate. 200 ml of DEAE Sepharose CL6B(Pharmacia) was added, and the slurry was stirred for l hour at 4C. The resin was collected in a Buchner funnel and packed into a 5 cm diameter column. Bound proteins were eluted with Buffer D + 400 mM ammonium sulfate. The DEAE eluate was flash frozen in liquid nitrogen and stored at -70C until use. The DEAE eluate was applied to the CTD column and analyzed as for HeLa extracts. All primary data were scanned and electronically processed as described (Koleske, A.J. and Young, R.A., Nature. 368:466-469 (1994)). Western blots were scanned as described (Donovan, R.S. et al . , Biotechnicrues. 17:660-661 A peptide corresponding to amino acids to amino acids 39-58 of hSRB7 was synthesized using the MAP system and used to prepare polyclonal antisera (Research Genetics) . The hSRB7 peptide was used to prepare affinity purified anti-hSRB7 antibody according to the manufacturer's directions, except that 1 volume of 1 M Na-Borate pH 8.5 was used to neutralize the eluate. The eluate was concentrated in a Centriprep 30 ultrafiltration unit (Amicon) . Aliquots of frozen calf thymus (1 kg) were placed in a nylon bag (The North Face) and broken with a hammer. The frozen pieces were added to 2 1 of 50 mM Tris-S04 pH 7.6, 10 mM EDTA, 10 mM EGTA, 5% glycerol, 0.1 mM DTT and protease inhibitors as in Buffer A. Aliquots of the calf thymus were mixed in a Waring blender for 2 minutes each. The mixed calf thymus was pooled and aliquots were blended for an additional 2 minutes. The blended thymus was spun at 5,000 r.p.m. for 30 min. in a Sorvall RC3B centrifuge. The supernatant was decanted through Miracloth (CalBiochem) , centrifuged again and decanted through Miracloth again. Ammonium sulfate was added to 30% saturation. After 15 minutes of stirring at 4C, the suspension was centrifuged at 5,000 r.p.m. for 1 hour in a Sorvall RC3B centrifuge. The supernatant was decanted and the pellet was resuspended in Buffer B (20 mM K-HEPES pH 7.6, 0.1 mM EDTA, 10% glycerol, 0.1 mM DTT, protease inhibitors as above) so that the conductivity equaled that of Buffer B + 75 mM ammonium sulfate. The suspension was centrifuged for 10 min. at 5,000 r.p.m. in a Sorvall RC3B. The supernatant was decanted and incubated with 500 g of damp phosphocellulose Pll (Whatman) precycled according to the manufacturer's directions and equilibrated in Buffer B + 75 mM ammonium sulfate. The slurry was stirred for l hour, filtered through a Buchner funnel, washed with Buffer B + 75 mM ammonium sulfate, and packed into a 5 cm diameter column. Bound proteins were eluted with Buffer B + 250 mM ammonium sulfate, frozen in liquid nitrogen, and stored at -70C until use. 100 ul of the phosphocellulose fraction was mixed with 200 ul Buffer B + 0.1% NP-40 and incubated with 5 ul of protein A-Sepharose (Pharmacia) for 1 hour. The fraction was centrifuged for 5 minutes in a microcentrifuge. The supernatant was incubated with 5 ul of protein A-Sepharose and 1.5 ug of affinity purified anti-SRB7 peptide antibody for 2 hours. The immune complexes were pelleted by a brief spin in a microcentrifuge and washed 4 times with 0.5 ml of 60 mM KC1, 50 mM Tris-Cl pH 7.9, 5 mM MgCl2, 2.5 mM MnCl2. Control immunoprecipitations were performed in the same manner except that 20 ug of hSRB7 peptide was used to block antigen-binding sites. Western blotting was performed as described above and probed with antibody directed against the C-terminus of hSRB7. In the control immunoprecipitation, pol II was added to all assays. In the anti-hSRB7 immunoprecipitation, exogenous pol II was omitted because pol II was known to be present in the immunoprecipitates. A phosphocellulose fraction was prepared as above. The 250 mM elute was flash frozen in liquid nitrogen and stored at -70°C. The extract was thawed and Buffer B was added so that the conductivity equaled that of Buffer B +150 mM ammonium sulfate. The extract was then spun at 5,000 r.p.m. for 10 minutes in an RC3B centrifuge (Sorvall) . The supernatant was decanted and applied to an 80 ml column of Heparin-Sepharose CL-6B at 3 ml/min. The column was washed with Buffer B + 200 mM ammonium sulfate and eluted with Buffer B + 500 mM ammonium sulfate. Eluted proteins were pooled, and ammonium sulfate was added to 60% saturation. After stirring for thirty minutes at 4°C, the suspension was centrifuged for 10 minutes at 10,000 r.p.m. in an SS- 343 rotor (Sorvall) . The supernatant was decanted and the pellet was stored at -70°C until use. The pellet was resuspended in 1.5 ml of Buffer B and dialyzed against 1 1 of Buffer B + 100 mM ammonium sulfate for 4 hours. The dialyzed sample was centrifuged for 10 minutes in a microcentrifuge and loaded onto a Sephacryl S-400 16/60 column (Pharmacia) at a flow rate of 0.5 ml/min. 1.5 ml fractions were collected. The column was calibrated with gel filtration standards (BioRad) run under similar conditions. Antibodies raised against TFIIH p89. TFIIE p56 and p34 (gifts of J. Kim, B. Shykind, and P. Sharp) and against M015 (gift of T. Makela and R. Weinberg) were used for Western Blotting. Example 10: Purification and Characterization of the Mammalian Holoenzyme Chromatography of calf thymus on Pll was as described for immunoprecipitations. Ammonium sulfate was added to the 250 mM eluate to achieve 35% saturation. After stirring at 4°C for 15 minutes, the suspension was spun at 17,000 r.p.m. for 10 minutes in an SS-34 rotor (Sorvall) . The supernatant was decanted and the pellet was stored at -70°C. The pellet was suspended in Buffer B such that the conductivity was equal to that of Buffer B + 150 mM ammonium sulfate. The resuspended pellet was centrifuged at 8,000 r.p.m. for 10 minutes in an SS-34 rotor (Sorvall) . The supernatant was decanted and loaded onto a 40 ml column of Heparin Sepharose CL6B. 1/25 volume of 1 M Tris-S04 pH 7.6 was added to the flow through. The fraction was then centrifuged at 8,000 r.p.m. for 10 minutes in an SS-34 rotor (Sorvall) and applied to a 5 ml HiTrap Q cartridge (Pharmacia) . Bound proteins were eluted with a 24 ml gradient of Buffer C (20 mM Tris-S04 pH 7.6, 0.1 mM EDTA, 10% glycerol, 0.1 mM DTT, protease inhibitors as for Buffer A) + 75 mM ammonium sulfate to Buffer C + 1000 mM ammonium sulfate. Fractions containing SRB7 were pooled and stored at -70°C until use. Buffer B was added to the pooled fractions such that the conductivity was equal to that of Buffer B + 75 mM ammonium sulfate. The pooled fractions were centrifuged at 8,000 r.p.m. for 10 minutes in an SS-34 rotor (Sorvall) . The supernatant was decanted and loaded onto a 5 ml Heparin HiTrap cartridge (Pharmacia) . Bound proteins were eluted with 30 ml gradient from Buffer B + 75 mM ammonium sulfate to buffer B + 1000 mM ammonium sulfate. Fractions containing SRB7 were pooled and stored at -70°C until use. Buffer C was added to one third of the pooled fractions such that the conductivity was equal to that of Buffer C + 75 mM ammonium sulfate. The pooled fractions were centrifuged at 8,000 r.p.m. for 10 minutes in an SS-34 rotor (Sorvall) . The supernatant was decanted and loaded onto a Mono Q HR 5/5 column (Pharmacia) . Bound proteins were eluted with a 20 ml gradient from Buffer C + 75 mM ammonium sulfate to buffer C + 1000 mM ammonium sulfate. Fractions containing SRB7 were pooled, flash frozen in liquid nitrogen, and sorted at -70°C until use. Pooled fractions were dialyzed against 1 1 of buffer B + 25 mM ammonium sulfate for 2 hours. Buffer B was added so that the conductivity was equal to that of Buffer B + 25 mM ammonium sulfate. The pooled fractions were filtered through a 0.2 um filter and loaded onto a Mono S, PC 1.6/5 (Pharmacia) . Bound proteins were eluted in 100 ul fractions with a 2 ml gradient from Buffer B + 25 mM ammonium sulfate to Buffer B + 1000 mM ammonium sulfate. In the second purification procedure, 4 volumes of Buffer C were added to one third of the pooled material from the Haparin HiTrap column. The pooled fractions were centrifuged at 8,000 r.p.m. for 10 minutes in an SS-34 rotor (Sorvall. The supernatant was decanted and loaded onto a 7.5 X 75 mm DEAE 5PW column (Toso-Haas) at a flow rate of 0.5 ml/min. Bound proteins were eluted with a 30 ml gradient from Buffer C + 75 mM ammonium sulfate to Buffer B + 750 mM ammonium sulfate. Fractions containing SRB7 were pooled, flash frozen in liquid nitrogen, and stored at -70°C until use. Pooled fractions were thawed and dialyzed against 1 1 of Buffer C for 2 hours. The dialyzed material was filtered through a 0.2 um filter and loaded onto a Mono Q, PC 1.6/5 (Pharmacia) at 0.1 ml/min. Bound proteins were eluted in 100 ul fractions with a 2 ml gradient from Buffer C + 75 mM ammonium sulfate to Buffer C + 1000 mM ammonium sulfate. Silver staining and Western blotting were performed. Transcription reactions were performed as described (Makela, T.P. et al . , Proc. Natl. Acad. Sci. U.S.A.. 92:5174-5178 (1995)). Holoenzyme was the peak fraction from the Mono S column. Protein preparations for all of the basal factors used here have been shown to be free of cross-contamination. In vitro transcription assays were used to test column purified holoenzyme (Mono S) for the ability to support specific transcription and for the presence of general transcription factors. The template was the adenovirus major late promoter with a linear topology. Products were obtained from a reaction containing all of the indicated factors, and with a single different factor omitted. Purified holoenzyme supports basal transcription when supplemented with general factors. Core RNA polymerase II or column purified holoenzyme were tested for their response to Gal4-VP16 in the presence or absence of the coactivators HMG-2 or PC4. The upper transcript is derived from a template containing the adenovirus major late promoter and 3 Gal4 binding sites. The lower transcript is derived from a control template containing the adenovirus major late promoter but no Gal4 binding sites. In the presence of coactivators, the holoenzyme supports five¬ fold levels of activation while core RNA polymerase II shows a two-fold level of activation. Example 11: Anti-SRB and Anti-SWI Antibodies Coprecipitate Holoenzyme All immunoprecipitations were done as described (Hengartner, C.J. et al . , Genes and Development. 9:897-910 (1995)) . Briefly, 50 μl of the DEAE(400) fraction was diluted 1:4 with modified transcription buffer (MTB) (50 mM HEPES KOH pH 7.3, 100 mM potassium acetate, 25 mM MgAc, 5 mM EGTA, lμM DTT, 10% glycerol, 0.01% NP-40, 1 mM PMSF, 2mM benzamidine, 2 μM pepstatin A, 0.6 μM leupeptin, and 2μg/ml chymostatin) minus the potassium acetate. 4 μg of ovalbumin, 4 μg HA-GST, and 2 μg BSA were added to each reaction prior to the addition of antibody. 0.4 μg of affinity purified C--SRBS, -0.15 μg of affinity purified α-SWI3, or 1.5 μg of affinity purified α-TGFβ were added to the respective reactions and allowed to incubate 2 hours at 4°C. 15 μl of goat anti-rabbit covalently linked to magnetic beads (Dynal) were then added and incubated for l hour at 4°C with constant agitation. Beads were precipitated with a magnet and washed three times in 200 μd MTB buffer. The final wash contained no NP-40. Proteins were eluted of the magnetic beads by boiling in 20 μl of sample buffer. All Western blots were performed as described (Koleske, A.J., and Young, R.A., Nature, 368:466-9 (1994) ) . Proteins were detected with the following antibodies: SRB2, 4, 5, 6 (Thompson, C.M.et al. , Cell. 73:1361-1375 (1993)) , SRB8, 9 (Hengartner, C.J. et al . , Genes and Development. 9:897-910 (1995)), SRB10, 11 (Liao, S.M. et al., Nature. 374:193-196 (1995)), SWI2/SNF2, SNF5 (gift of B. Laurent), SWI3 (gift of C. Peterson) , SNF11 (gift of I. Treich and M. Carlson), TFIIEα and TFIIEjS. The production of antibodies, polyclonal and monoclonal are well-known to those of skill in the art and antibodies to additional components of the RNA polymerase II holoenzyme can be produced accordingly. Quantitative Western blots were performed as described in Koleske A.J. and Young R.A., Nature, 368:466-469 (1994). Recombinant standards were SRB5 Thompson, CM. and Young, R.A., Proc. Natl. Acad. Sci. USA. (1995) , GST-SNF2/SWI2 1256 . 1703 and GSTSNF5 W93 (gifts of B. Laurent) . GST proteins were purified as described (Smith, D.B. and Johnson, K.S., Gene. 67:31-40 (1988)). Concentrations of recombinant proteins were determined using a colorimetric assay (BioRad) with bovine serum albumin as a standard. SRB regulatory proteins are found tightly and exclusively associated with other components of the RNA polymerase II holoenzyme in cell extracts. If SWI and SNF proteins are subunits of the RNA polymerase II holoenzyme, then antibodies against SRB5 should precipitate both the holoenzyme and SWI/SNF proteins from crude extracts. The results in demonstrate that this is indeed the case. SWI2/SNF2, SWI3 and SNF5 proteins coprecipitate with holoenzyme obtained through SRB5 immunoprecipitation. The fraction of SWI and SNF proteins immunoprecipitated from the crude extract appears to be the same as that of the SRB proteins. Control proteins introduced into the crude lysate did not coprecipitate, indicating that the immunoprecipitate was specific for the holoenzyme. When the immunoprecipitation experiment was carried out with antibody against SWI3, essentially identical results were obtained. The SWI/SNF and SRB proteins were immunoprecipitated from the crude extract with similar efficiency whether the immunoprecipitating antibody used was directed against SRB5 or SWI3. A control experiment with antibody against TGFjS failed to precipitate SWI/SNF or SRB proteins. These results indicate that SRB and SWI/SNF proteins are tightly associated with one another, and form as SRB/SWI/SNF complex. Example 12: Purified Holoenzyme Contains SWI/SNF Proteins Holoenzyme was purified and transcription assays for holoenzyme were done as described in Koleske and Young, 1994. Mediator was purified as described in Hengartner, C.J. et al . , Genes and Development. 9:897-910 (1995) . Antibodies against selected SWI and SNF proteins were used to determine whether these proteins coelute with the RNA polymerase II holoenzyme in the final purification step of the holoenzyme. The data demonstrate that SN2/SWI2, SNF5, SWI3 and SNF11 proteins coelute with other known components of the holoenzyme and with transcription activity. The holoenzyme contains stoichiometric amounts of RNA polymerase II, SRB proteins, and general transcription factors. To ascertain whether the SWI/SNF proteins are stoichiometric components of the holoenzyme, the amounts of SNF2 and SNF5 were estimated by Western blot analysis with various amounts of recombinant proteins as standards. These data indicate that the purified RNA polymerase II holoenzyme contains approximately equimolar amounts of SNF2, SNF5 and SRB5, the latter being a standard against which other holoenzyme components have previously been compared. Since yeast cells contain between 2000 and 4000 molecules of RNA polymerase II holoenzyme, it appears that there are at least this number of SWI2/SNF2 and SNF5 molecules per cell. Example 13: SWI/SNF Proteins Are Components of CTD-Bindinq SRB Complexes SRB/SWI/SNF Complex Purification Whole cell extract was prepared from Red Star Yeast as described in Thompson, CM. et al . , Cell. 73:1367-1375 (1993) 1.2L of the ammonium sulfate pellet was centrifuged for 30 minutes at 5,000 RPM. in an RC3B centrifuge (Sorvall) . The pellet was resuspended in 900 ml of Buffer A (20 mM K-Hepes pH 7.61 mM EDTA 1 mM DTT 20% glycerol, and protease inhibitors (Thompson, CM. et al . , Cell. 73:1367-1375 (1993)). The suspension was centrifuged again for 30 minutes at 5,000 RPM. in an RC3B centrifuge (Sorvall) . The supernatant was mixed with 200 g (dry) of BioRex 70 and stirred for 20 minutes. The suspension was packed into a column with a 5 cm diameter and washed with 1.51 of Buffer A + 100 mM KOAc. Bound proteins were eluted with Buffer A + 600 mM KOAc. Fractions containing protein were pooled, frozen in liquid nitrogen and stored at -70°C until use. Eluates from 2 BioRex columns (320 ml, 1.0 g protein) were thawed and pooled. 320 ml of Buffer A + 2% Triton X-100 were added and the mixture was centrifuged for 30 minutes at 12,000 RPM. in a GSA rotor (Sorvall) . The supernatant was loaded onto a 15 ml CTD affinity column prepared as described in Thompson, CM. et al . , Cell. 73:1367-1375 (1993) at a flow rate of 200 ml/hr. The column was washed with 100 ml of Buffer A + 300 mM KOAc + 1% Triton X-100, 100 ml or Buffer A + 300 mM KOAc. Bound proteins were eluted with Buffer A + 300 mM KOAc + 1 M Urea at a flow rate of 25 ml/hr. Fractions containing protein (3.7 mg) were pooled, frozen in liquid nitrogen, and stored at -70°C The CTD column was equilibrated with Buffer A + 300 mM KOAc + 1% Triton X-100 and the flow through was loaded again. The column was washed and eluted as before. Fractions containing protein (1.8 mg) were pooled, frozen in liquid nitrogen, and stored at -70°C The CTD eluates were pooled, diluted with 1.5 volumes of Buffer A + 0.01% NP-40, and centrifuged for 10 minutes at 17,000 RPM. in an SS-34 rotor (Sorvall). The supernatant was loaded onto a Mono S HR 5/5 (Pharmacia) at a flow rate of 0.3 ml/min. The column was washed with 3 ml of Buffer A + 120 mM KOAc + 0.01% NP-40. Bound proteins were eluted with a 20 ml gradient of Buffer A +0.01% NP-40 from 120 mM to 1000 mM KOAc. Fractions were frozen in liquid nitrogen and stored at -70°C until use. Fractions containing SRB4 and SRB5 as assayed by Western blotting were pooled and diluted with 2 volumes of Buffer B (20 mM Tris OAc pH 7.6 + 20% glycerol + 1 mM DTT + 0.01% NP-40 + protease inhibitors) . The mixture was centrifuged for 5 minutes in a microcentrifuge. The supernatant was loaded onto a Mono Q HRR 5/5 column (Pharmacia) at a flow rate of 0.3 ml/min. The column was washed with 1 ml of Buffer B + 200 mM KOAc. Bound proteins were eluted with a 40 ml gradient of Buffer B from 200 mM to 2000 mM KOAc. The yield of SRB complex was approximately 100 μg. 1 μl of each fraction was analyzed by silver staining. 7.5 μl - lOμl of each fraction were analyzed by Western blotting. Genetic evidence indicates the SRB regulatory proteins and the RNA polymerase II C-terminal domain (CTD) have related functions in transcription initiation, and that these involve the response to transcriptional regulators. Since the SWI and SNF proteins are also involved in activation of a wide variety of genes, and mutations in SWI and SNF genes can produce phenotypes similar to those observed with mutations in SRB genes, it was investigated whether SWI and SNF proteins are associated with the SRB complex. The SRB protein complex can be released from the holoenzyme when the latter is treated with monoclonal antibodies against the CTD, and this preparation has been called mediator (Kim, Y.J. et al . Cell. 77:599-608 (1994) ) . A mediator complex was prepared according to Kim et al . This mediator complex was confirmed to have the coactivator activity previously described and further, it was demonstrated that the mediator contains all of the SRB proteins (Hengartner, C.J. et al. Genes and Development. 9:897-910 (1995)). When this mediator preparation was assayed for the presence of SNF2/SWI2, SNF5 and SWI3 proteins by Western blot, all three SWI/SNF proteins were found. The SRB complex can also be isolated from crude extracts using a recombinant CTD column (Thompson, CM. et al . Cell. 73:1361-1374 (1993)). An SRB complex was purified extensively by using a recombinant GST-CTD column, followed by chromatography with mono S and mono Q columns. The SRB, SWI, and SNF proteins bind to a GST-CTD column, but not to a control GST column, indicating that they bind specifically to the CTD. Sliver stain and Western blot analysis confirm that a multiprotein complex containing SRB proteins and each of the three SWI/SNF proteins assayed comigrate from the mono Q column. There are approximately 25 polypeptides in this complex and several correspond in size to previously identified SRB, SWI, and SNF proteins. No signals were obtained when Western Blots containing the SRB/SWI/SNF complex were probed with antibodies against RNA polymerase II, TBP, TFIIB, or the TFB1 subunit of TFIIH. These results indicate that the SRB complex is in fact an SRB/SWI/SNF complex and furthermore, that the SWI and SNF proteins interact with the holoenzyme, at least in part through their association with RNA polymerase II CTD. Example 14 : Nucleosome Disruption Activity in Holoenzyme and SRB/SWI/SNF Complex The PH MLT or PH MLT(+3) restriction fragments were assembled into rotationally phased mononucleosome particles, purified by glycerol gradient centrifugation, and assayed as described by Imbalzano, A.M. et al . , Nature. 370:481-485 (1994). At the nucleosome concentrations and reaction conditions employed in this and previous studies, nucleosomes were determined to be stable on the basis of resistance to micrococcal nuclease, the appearance of a 10 bp repeat pattern upon DNAse I digestion, and exhibition of reduced mobility upon electrophoresis in native polyacrylamide gels. The appearance of free DNA due to nucleosome dissociation was not observed in any of these experiments. Holoenzyme fractions were the same as those used in Example 11. 0.3 μl of each fraction was assayed in the presence of 4 mM ATP. For the titration of holoenzyme, 0 μl, 0.015 μl, 0.05 μl, 0.15μl, 0.5 μl of fraction 60 was used respectively with and without 4 mM ATP as indicated. SRB/SWI/SNF- fractions were as those used above. 1.7μl of each fraction was assayed in the presence of 4 mM ATP. For the titration in 0 μl, 0.07 μl, 0.2 μl, 0.7 μl, and 2.0 μl of fraction 24 was used respectively with and without 4 mM ATP. Binding of yTBP and yTHIIA to nucleosomes containing the PH MLT(+3) restriction fragment was performed as previously described in Imbalzano, A.N. et al . , Nature, 370:481-485 (1994). All reactions contained 4 mM ATP. Following a 30 minute incubation at.30°C in the presence or absence of holoenzyme, increasing amounts of yTBP in the presence of yTFIIA were added. TBP concentrations were 0, 0.04 micromolar, 0.4 micromolar and 4 micromolar. 1.5 micromolar yTFIIA was also added to all reactions. Reactions were treated with holoenzyme, alone, in the presence of 4 mM ATP or in the presence of 4 mM ATPγS for 30 minutes at 30°C, followed by addition of 4 micromolar yTBP in the presence of 1.5 micromolar yTHIIA. Recombinant yTBP was purified as described (Hoey, T. et al., Cell. 61:1179-1186 (1990)), except that the heparin peak was further purified on a Mono S HR5/5 FPLC column (Pharmacia) . Recombinant yTFIIA was purified as described (Ranish, A.A. et al . , Science. 255:1127-1129 (1992) ) . Previous evidence that SWI1. SWI2, SWI3, SNFS, SNF6, and SNF11 gene products can be isolated as a large multisubunit complex capable of altering nucleosome structure led us to investigate whether the purified RNA polymerase II holoenzyme and the SRB/SWI/SNF complex were able to alter nucleosome structure. Mononucleosome particles were reconstituted from purified histone octamers and a DNA fragment containing two copies of an artificial phasing sequence (Shrader, T.E., and Crothers, D.M., Proc Natl Acad Sci U S A. 86, 7418-22 (1989)). Digestion of the mononucleosomes with DNAse I showed a 10 bp cleavage ladder typical of a rotationally phased nucleosome. Fractions in the last chromatographic step in the purification of the holoenzyme were mixed with mononucleosomes and assayed for the ability to alter nucleosome structure, which can be visualized by changes in the accessibility of the nucleosome to DNAse I cleavage. The results show that nucleosome disruption activity coeluted with the RNA polymerase holoenzyme. The ability of the SRB/SWI/SNF complex to alter nucleosome structure was assayed in a similar experiment using fractions from the last step in the SRB/SWI/SNF purification. The results show that nucleosome disruption activity coeluted with the SRB/SWI/SNF complex. Further analysis of the RNA polymerase II holoenzyme and SRB/SWI/SNF complex showed that the nucleosome disruption activity was ATP dependent. In addition, purified core RNA polymerase II showed no nucleosome alteration capability. These data indicate that the SRB/SWI/SNF complex contributes chromatin remodeling activity to the RNA polymerase II holoenzyme. Example 15: Purified Holoenzyme And The SRB/SWI/SNF Complex Disrupts Plasmid Chromatin Supercoiling Reduction Assay Plasmid chromatin was assembled and purified as described (Kwon, H. et al . , Nature. 370:477-481 (1994)). Reactions, total volume 12.5 μl, contained chromatin (2ng DNA), 1 U Topoisomerase I (Promega), 2.5 μl -30% Glycerol Gradient Buffer, 7 μl Buffer A minus KC1, 7 mM MgCl 2 , 50-100 mM KOAc (final) , 4 mM ATP where indicated, and 2 μl holoenzyme mono S fractions or 1 μl SRB/SWI/SNF complex mono Q fractions. Reactions were stopped after 90 minutes at 30°C by addition of 6 μl stop buffer (3% SDS, 100 mM EDTA, 50 mM Tris HCl pH 8.0, 25% Glycerol, 2 mg/ml proteinase K) . Reactions were incubated for 90 minutes at 37° and resolved on a 2% agarose gel (50 mM Tris-Phosphate pH 7.3, 1 mM EDTA) for 40 hrs, at 40V. Gels were dried and exposed to film. To further characterize the nucleosome-disruption capabilities of the holoenzyme and the SRB/SWI/SNF complex, a supercoiling reduction assay was used. In this assay chromatin is assembled onto a relaxed closed-circular plasmid which is subsequently purified by glycerol gradient centrifugation. Each assembled nucleosome introduces approximately one negative supercoil to the plasmid, which can be resolved by agarose gel electrophoresis after the removal of histones. When no protein is added to the nucleosome-assembled plasmid, it is highly supercoiled. Fractions from the last column of the holoenzyme purification were tested for their ability to disrupt nucleosome structure and thereby reduce supercoiling in the presence of added Topoisomerase I. This activity coelutes with holoenzyme transcription activity, with the SRB and SWI/SNF proteins, and with nucleosome-core disruption activity. The supercoiling-reduction activity was dependent on ATP, as has been shown for the human SWI/SNF complex (Kwon, H. et al . Nature, 370:477-481 (1994)). Repeating the experiment using fractions from the last column of the SRB/SWI/SNF complex shows that this complex also has an ATP-dependent supercoiling-reduction activity. Example 16: Holoenzyme Facilitates the Binding of TBP to Nucleosomes Previous work has shown that both yeast and human SWI/SNF complexes can facilitate transcription factor binding to nucleosomal DNA containing the relevant factor binding site The holoenzyme described herein was tested as to whether it could increase the binding of TBP to a mononucleosome containing a TBP binding site. With holoenzyme and ATP present, TBP and TFIIA bound to the mononucleosome at TBP concentrations of 4x10".., while no TBP/TFIIA binding was observed in the absence of holoenzyme. This holoenzyme-facilitated TBP binding might be caused by the stabilizing effects of the additional protein-protein and protein-DNA interactions that occur in the presence of RNA polymerase and general transcription factors, by the ATP dependent nucleosome disruption effects of SWI/SNF, or by a combination of both effects. To address this issue, whether facilitated TBP binding was ATP dependent was tested and partial protection of the TATA region on the mononucleosome when ATP is withheld or when ATPγS is used instead of ATP was observed. However, addition of ATP enhanced the TBP binding as indicated by the increased protection from DNAse I cleavage over the TATA box, the extension of the footprint in the 5' direction, and the appearance of a hypersensitive band in the 3' direction. Thus, it appears that the holoenzyme can partially stabilize binding of TBP and TFIIA to a mononucleosome in the absence of ATP. However, the full effect of holoenzyme-facilitated TBP binding requires ATP, presumably because it involves the ATP-dependent nucleosome disruption activity of the SWI/SNF proteins. Equivalents Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims:

Claims: What is claimed is: CLAIMS 1. A purified RNA polymerase II holoenzyme comprising RNA polymerase II and one, or more regulatory proteins. 2. A purified RNA polymerase II holoenzyme of Claim 1 wherein the regulatory proteins comprise one, or more SRB proteins. 3. A purified multisubunit RNA polymerase II holoenzyme which: a) comprises at least one SRB protein and RNA polymerase II; b) has SRB and RNA polymerase activity; and c) is responsive to a transcriptional activator. 4. A purified multisubunit RNA polymerase II holoenzyme of Claim 3 wherein the holoenzyme comprises regulatory proteins including nine SRB proteins transcription factors b, e, and g, or homologs thereof, and RNA polymerase II, said holoenzyme having a molecular weight of approximately 1-4 Md. 5. A purified multisubunit RNA polymerase II holoenzyme of Claim 3 wherein the holoenzyme comprises regulatory proteins including hSRB7, transcription factors TFIIE and TFIIH, or homologs thereof, and RNA polymerase II, said holoenzyme having a molecular weight of approximately 1-4 Md. 6. A purified RNA polymerase II holoenzyme of Claim 1 wherein the regulatory proteins comprise or more SWI/SNF proteins. 7. A purified RNA polymerase II holoenzyme of Claim 6 wherein the SWI/SNF proteins comprise a complex of SRB proteins and other regulatory components . 8. A purified RNA polymerase II holoenzyme of Claim 6 wherein the SWI/SNF protein comprise SWI/SNF proteins selected from the group consisting of SWI1, SWI2/SFN2, SWI3, SNF5, SNF6 and SNF11. 9. A purified multisubunit RNA polymerase II holoenzyme which: a) comprises at least one SRB protein, at least one SWI/SNF protein and RNA polymerase II; b) has SRB, SWI/SNF and RNA polymerase activity; and c) is responsive to a transcriptional activator. 10. A purified multisubunit RNA polymerase II holoenzyme of Claim 9 wherein the holoenzyme comprises regulatory proteins including nine SRB proteins, transcription factors b, e and g, or homologs thereof, one, or more SWI/SNF proteins and RNA polymerase II and has a molecular weight of approximately 1-4 Md. 11. Isolated DNA which encodes a transcription regulatory factor, wherein the DNA is and is selected from the group consisting of: a) DNA encoding a transcription regulatory factor which is a polypeptide having the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, or SEQ ID NO: 37; b) SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, and SEQ ID NO: 36; c) the complementary strand of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 36; d) DNA which hybridizes to SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: or 17, SEQ ID NO: 36 under conditions of high stringency; and e) DNA which hybridizes to the complementary Strand of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 36 under stringent conditions. 12. Isolated DNA which encodes a transcription regulatory factor, wherein the DNA and is selected from the group consisting of: a) DNA encoding a transcription regulatory factor which is a polypeptide having the amino acid sequence of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, or SEQ ID NO: 37; b) SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, and SEQ ID NO: 36; c) the complementary strand of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 36; d) DNA which hybridizes to SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 36 under conditions of high stringency; and e) DNA which hybridizes to the complementary strand of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 36 under stringent conditions. 13. Antibodies reactive with a transcription regulatory factor which is a polypeptide having an amino acid sequence selected from the group consisting of: SEQ ID NO: 2; SEQ ID NO: 4; SEQ ID NO: 6; SEQ ID NO: 8; SEQ ID NO: 10; SEQ ID NO: 12; SEQ ID NO: 14; SEQ ID NO: 16; SEQ ID NO: 18 and SEQ ID NO: 37. 14. A method of inhibiting gene transcription in a cell comprising introducing into the cell an antibody selected from the group consisting of: an antibody that binds to a SRB protein, or an antibody that binds to a SWI/SNF protein, wherein the antibody binds to the SRB protein or SWI/SNF protein, thereby preventing the formation of an RNA polymerase II holoenzyme complex. 15. A method of inhibiting gene transcription in a cell comprising introducing into the cell an antibody selected from the group consisting of: an antibody that binds to a SRB protein, or an antibody that binds to a SWI/SNF protein, wherein the antibody binds to the SRB protein or SWI/SNF protein, thereby preventing the formation of a functional RNA polymerase II holoenzyme complex. 16. A method of modifying gene transcription in a cell comprising introducing into the cell an antibody selected from the group consisting of: an antibody that binds to a SRB protein, or an antibody that binds to a SWI/SNF protein, wherein the antibody binds to the SRB protein or SWI/SNF protein, thereby modifying the ability of the SRB protein to process regulatory signals. 17. A method of inhibiting gene transcription in a cell comprising introducing into the cell an effective amount of a substance which binds to at least one SRB protein, or, at least one SWI/SNF protein, thereby preventing the formation of an RNA polymerase II holoenzyme complex. 18. A method of inhibiting gene transcription in a cell comprising introducing into the cell an effective amount of a substance which binds to at least one SRB protein, or, at least one SWI/SNF protein, thereby preventing the formation of a functional RNA polymerase II holoenzyme complex. 19. A method of Claim 18 wherein the SRB protein has kinase activity and the substance binds to the SRB protein, thereby modifying the kinase activity of the SRB protein. 20. A method of Claim 18 wherein the SWI/SNF protein has chromatin remodeling activity, and the substance binds to the SWI/SNF protein, thereby modifying the chromatin remodeling activity of the SWI/SNF protein. 21. A method of inhibiting gene transcription in a cell, comprising introducing into the cell an effective amount of a substance which binds to the carboxyl terminal domain of RNA polymerase II, thereby modifying the ability of the RNA polymerase II to interact with an SRB protein, or SRB/SWI/SNF protein complex. 22. A method of modifying gene transcription in a cell, comprising introducing into the cell an effective amount of a substance which binds to at least one SRB protein, thereby modifying the ability of the SRB protein to process regulatory signals. 23. A method of Claim 22 wherein the substance binds to SRB8 or SRB9, thereby increasing gene transcription. 24. A method of Claim 22 wherein the substance binds to SRB2 or SRB5, thereby decreasing gene transcription. 25. A method of modifying gene transcription in a cell, comprising introducing into the cell an effective amount of a substance that inhibits transcription of one or more of the SRB genes or SWI/SNF genes. 26. A method of modifying gene transcription in a cell, comprising inhibiting or promoting post- translational modification of a SRB or SWI/SNF protein. 27. A method of modifying gene transcription in a cell, comprising introducing into the cell an effective amount of a substance that inhibits translation of mRNA encoding one or more of the SRB gene products or SWI/SNF gene products. 28. A method of inhibiting gene transcription in a cell, comprising introducing into the cell DNA encoding a peptide which inhibits the activity of an SRB protein, or a SWI/SNF protein, by binding to the SRB protein, or to the SWI/SNF protein, or binding to a site on one of the components of the RNA polymerase II holoenzyme to which the SRB protein or SRB/SWI/SNF complex binds, thereby preventing the formation of an RNA polymerase II holoenzyme. 29. A method of inhibiting gene transcription in a cell, comprising introducing into the cell DNA encoding a peptide which is expressed in the cell, wherein the peptide is one which inhibits the activity of an SRB protein, or a SWI/SNF protein, by binding to the SRB protein, or to the SWI/SNF protein, or binding to a site on one of the components of the RNA polymerase II holoenzyme to which the SRB protein, or SRB/SWI/SNF complex binds, thereby preventing the formation of a functional RNA polymerase II holoenzyme. 30. A method of modifying gene transcription in a cell, comprising introducing into the cell DNA encoding a peptide which is expressed in the cell, wherein the peptide is one which inhibits the activity of an SRB protein, or a SWI/SNF protein, by binding to the SRB protein, or to the SWI/SNF protein, or binding to a site on one of the components of the RNA polymerase II holoenzyme to which the SRB protein, or SRB/SWI/SNF complex binds, thereby modifying the ability of the SRB protein to process regulatory signals or thereby modifying the ability of the SWI/SNF protein complex to remodel chromatin structure. 31. A method of increasing gene transcription in a cell, comprising introducing into the cell DNA encoding a peptide which is expressed in the cell, wherein the peptide is one which encodes a SRB protein, or a SWI/SNF protein, capable of forming an RNA polymerase II holoenzyme, thereby increas- ing the formation of an RNA polymerase II holo¬ enzyme. 32. A method of inhibiting gene transcription in a cell, comprising introducing into the cell DNA encoding a mutant SRB protein, or SWI/SNF protein, which is expressed in the cell, wherein the mutant SRB or SWI/SNF protein is incapable of forming an RNA polymerase II holoenzyme, thereby preventing the formation of a RNA polymerase II holoenzyme. 33. A method of inhibiting gene transcription in a cell,comprising introducing into a cell DNA encoding a biologically inactive mutant SRB protein, or a SWI/SNF protein, which is expressed in the cell, wherein the biologically inactive mutant SRB or SWI/SNF protein is capable of forming an RNA polymerase II holoenzyme, thereby preventing the formation of a functional RNA polymerase II holoenzyme. 34. A method of modifying gene transcription in a cell, comprising introducing into the cell DNA encoding a mutant SRB protein which lacks the ability to process regulatory signals. 35. A method of modifying gene transcription in a cell comprising introducing into the cell DNA encoding a mutant SWI/SNF protein which lacks the ability to remodel chromatin structure. 36. A DNA probe which hybridizes to DNA encoding a SRB protein or a SWI/SNF protein. 37. A DNA probe of Claim 36 which hybridizes to DNA selected from the group consisting of: SEQ ID NO: 1; SEQ ID NO: 3; SEQ ID NO: 5; SEQ ID NO: 7; SEQ ID NO: 9; SEQ ID NO: 11; SEQ ID NO: 13; SEQ ID NO: 15; SEQ ID NO: 17 and SEQ ID NO: 36. _«•- • 38. A method of detecting a SRB nucleic acid, comprising DNA or RNA in a biological sample, comprising the steps of: a) rendering nucleic acid present in the sample available for hybridization with complementary DNA or RNA thereby producing hybridizable nucleic acid; b) contacting the nucleic acid produced in step (a) with a DNA or RNA probe which is a nucleic acid sequence complementary to all, or a portion of, a nucleic acid sequence encoding a SRB protein, under conditions appropriate for hybridization of comple¬ mentary nucleotide sequences to occur; and c) detecting hybridization of nucleic acid with the probe, wherein hybridization of nucleic acid present in the sample with the probe is indicative of the SRB nucleic acid. 39. The method of Claim 38 wherein the probe is detectably labelled. 40. An immunoassay for detecting or quantifying the presence of SRB protein in a cell or biological sample, comprising the steps of: a) reacting the cell or fluid with an antibody which binds to the SRB protein thereby forming an antibody/SRB protein complex; and b) detecting or quantifying the antibody/SRB wherein detection of the complex is indicative of the presence of SRB protein. 41. An immunoassay assay according to Claim 40 wherein the antibody is detectably labeled. 42. A method of treating a disease condition resulting from an alteration or deletion of a SRB gene, or SWI/SNF gene, which comprises adding an effective amount of a SRB or SWI/SNF gene product to diseased cells. 43. The method of Claim 42 wherein the effective amount of the SRB gene product, or SWI/SNF gene product is added to the diseased cells by gene transfer technology. 44. A method of in vi tro transcription of a DNA sequence, comprising the steps of: a) providing DNA to be transcribed, transcription factor a, or a homolog thereof, and TATA-binding protein; b) admixing the DNA, transcription factor and binding protein of step a) with purified RNA polymerase II holoenzyme; and c) maintaining said admixture of step b) under conditions sufficient for transcription of the DNA. 45. A method of identifying a substance that modifies gene transcription, comprising the steps of: a) combining : (i) DNA to be transcribed; (ϋ) transcription factor a, or a homolog thereof; (iii) TATA-binding protein; (iv) a substance to be assessed for its ability to modify gene transcription; and (v) purified RNA polymerase II holoenzyme, thereby producing a test mixture; b) maintaining the test mixture of step a) under conditions sufficient for transcription of the DNA; and c) determining the extent to which DNA transcription occurs in the test mixture and comparing the result with the extent to which DNA transcription occurs in the absence of the substance. 46. A purified multiprotein complex comprising one, or more SRB proteins and one, or more SWI/SNF proteins, said complex having activity to regulate gene transcription. 47. A complex of Claim 46 wherein the activity is chromatin remodeling activity. 48. A method of identifying a protein that has activity functionally equivalent to the activity of a SRB or SWI/SNF protein comprising evaluating the ability of the candidate protein to complement the activity of a deleted SRB or SWI/SNF protei 49. A method of identifying a protein that has activity functionally equivalent to the activity of the SRB or SWI/SNF protein, comprising the steps of: a) inhibiting, partially or completely, the activity of SRB or SWI/SNF protein in the RNA polymerase II holoenzyme; b) associating the candidate protein with the RNA polymerase II holoenzyme; and determining the activity of the RNA polymerase II holoenzyme associated with the candidate protein, wherein if the candidate protein is functionally equivalent to the inhibited SRB or SWI/SNF protein, the RNA polymerase II holoenzyme initiates gene transcription.

Inventors: CHAO DAVID M, KOLESKE ANTHONY J, THOMPSON CRAIG M, YOUNG RICHARD A, CHAO, DAVID, M., KOLESKE, ANTHONY, J., THOMPSON, CRAIG, M., YOUNG, RICHARD, A.
Applicants: WHITEHEAD BIOMEDICAL INST, WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
Application year: 1996
Main classification: C12N9
IPC codes: C07K14, C07K16, C12N9, C12N15, G01N33